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Genetic analysis of multiple bipolar
disorder and schizophrenia cohorts
reveals loci and polygenic risk scores that
differentiate the clinical symptoms of
these two highly correlated disorders.Psychiatric
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Schizophrenia and bipolar disorder are two distinct
diagnoses that share symptomology. Understanding
the genetic factors contributing to the shared and
disorder-specific symptoms will be crucial for
improving diagnosis and treatment. In genetic data
consisting of 53,555 cases (20,129 bipolar disorder
[BD], 33,426 schizophrenia [SCZ]) and 54,065 con-
trols, we identified 114 genome-wide significant loci
implicating synaptic and neuronal pathways shared
between disorders. Comparing SCZ to BD (23,585
SCZ, 15,270 BD) identified four genomic regions
including one with disorder-independent causal
variants and potassium ion response genes as
contributing to differences in biology between the
disorders. Polygenic risk score (PRS) analyses iden-
tified several significant correlations within case-only
phenotypes including SCZ PRS with psychotic fea-
tures and age of onset in BD. For the first time, we
discover specific loci that distinguish between BD
and SCZ and identify polygenic components under-
lying multiple symptom dimensions. These results
point to the utility of genetics to inform symptomol-
ogy and potential treatment.INTRODUCTION
Bipolar disorder (BD) and schizophrenia (SCZ) are severe psy-
chiatric disorders and among the leading causes of disability
worldwide (Whiteford et al., 2013). Both disorders have signifi-
cant genetic components with heritability estimates ranging
from 60% to 80% (Nöthen et al., 2010). Recent genetic and
epidemiological studies have demonstrated substantial overlap
between these two disorders, with a genetic correlation from
common variation near 0.6–0.7 (Lee et al., 2013) and high relative
risks (RR) among relatives of both BD and SCZ patients (RRs for
parent/offspring: BD/BD: 6.4, BD/SCZ: 2.4; SCZ/BD: 5.2, SCZ/
SCZ: 9.9) (Lichtenstein et al., 2009). Despite shared genetics
and symptomology, the current diagnostic systems (DSM Li-
brary; World Health Organization) adhere to historical distinc-
tions from the late 19th century and represent BD and SCZ as in-
dependent categorical entities differentiated on the basis of their
clinical presentation, with BD characterized by predominant
mood symptoms, mood-congruent delusions, and an episodicdisease course and SCZ considered a prototypical psychotic
disorder. Identifying genetic components contributing to both
disorders will provide insight into the biology underlying the
shared symptoms of the disorders.
While the shared genetic component is substantial, studies to
date have also implicated genetic architecture differences be-
tween these two disorders (Curtis et al., 2011; Ruderfer et al.,
2014). A polygenic risk score (PRS) created from a case-only
SCZ versus BD genome-wide association study (GWAS) signifi-
cantly correlated with SCZ or BD diagnosis in an independent
sample (Ruderfer et al., 2014), providing the first evidence that
differences between the disorders also have a genetic basis.
An enrichment of rare, moderate to highly penetrant copy-num-
ber variants (CNVs) and de novo CNVs are seen in SCZ patients
(Gulsuner and McClellan, 2015; Kirov et al., 2012; Marshall et al.,
2017; Stone et al., 2008; Szatkiewicz et al., 2014), while the
involvement of CNVs in BD is less clear (Green et al., 2016).
Although the role of de novo single nucleotide variants in BD
and SCZ has been investigated in only a handful of studies,
enrichment in pathways associated with the postsynaptic den-
sity has been reported for SCZ but not BD (Fromer et al., 2014;
Kataoka et al., 2016). Identifying disorder-specific variants and
quantifying the contribution of genetic variation to specific symp-
tom dimensions remain important open questions. Character-
izing these genetic differences will facilitate an understanding
of the dimensions of the disorders instead of the dichotomous
diagnosis. For example, we have shown that SCZ patients with
greater manic symptoms have higher polygenic risk for BD (Ru-
derfer et al., 2014). These findings demonstrate shared genetic
underpinnings for symptoms across disorders and may enable
us to characterize patients by genetic liability to symptom di-
mensions, thereby informing disease course and treatment.
Here, we utilize large collections of genotyped samples for BD
and SCZ along with clinically relevant measures identifying 28
subphenotypes to address three questions: (1) are there specific
variants, genes, or pathways that are either shared by or differ-
entiate BD and SCZ; (2) are the shared symptoms between these
disorders driven by the same underlying genetic profiles; and (3)
can we demonstrate independent genetic signatures for sub-
phenotypes within these disorders?RESULTS
Shared Genetic Contribution to BD and SCZ
We performed association analysis of BD and SCZ combined
into a single phenotype, totaling 53,555 cases (20,129 BD,
33,426 SCZ) and 54,065 controls on 15.5 million SNP alleleCell 173, 1705–1715, June 14, 2018 ª 2018 Elsevier Inc. 1705
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Figure 1. Associated Genomic Loci Shared and Divergent between BD and SCZ
(A) Odds ratios (OR) and SE from independent datasets of BD (blue) and SCZ (red) for each of the 114 genome-wide significant variants in the BD and SCZ versus
controls GWAS.
(B) Manhattan plot for SCZ versus BD GWAS.dosages imputed from 1000 Genomes phase 3 (The 1000 Ge-
nomes Project Consortium, 2015). Logistic regression was per-
formed controlling for 13 principal components of ancestry,
study sites, and genotyping platform. We identified 11,231
SNPs with p value below our genome-wide significance (GWS)
threshold of 53 108. After grouping SNPs in linkage disequilib-
rium with each other (r2 > 0.2), 114 genomic risk loci remained.
For the most significant variant in each of the 114 GWS loci,
we performed conditional analysis with any GWS hit within
1Mb of the extent of the locus from the previously performed sin-
gle disease GWAS of SCZ (Schizophrenia Working Group of the
Psychiatric Genomics Consortium, 2014) and BD (Stahl et al.,
2017) and identified 32 loci that were independently significant,
defined strictly as no single disease locus within 1 Mb or a
GWS p value after conditional analysis (Table S1). We further
performed gene-set-based tests using MAGMA (de Leeuw
et al., 2015) across 10,891 curated pathways (Watanabe et al.,1706 Cell 173, 1705–1715, June 14, 20182017) and identified 8 pathways surpassing Bonferroni correc-
tion (p < 4.63 106) with all but one pathway implicating synaptic
and neuronal biology (Table S2a). Establishing independent con-
trols (see STAR Methods) allowed us to perform disorder-spe-
cific GWAS in 20,129 BD cases versus 21,524 BD controls and
33,426 SCZ cases and 32,541 SCZ controls. Using these results,
we compared disorder-specific effect sizes of these 114 loci,
showing that despite contributing to the combined phenotype,
subsets of variants had larger effects in SCZ compared to BD
and vice versa (Figure 1A).
Differentiating Genetic Contribution to BD and SCZ
To identify loci with divergent effects on BD and SCZ, we per-
formed an association analysis comparing 23,585 SCZ cases
with 15,270 BD cases matched for shared ancestry and geno-
typing platform (see STAR Methods; Figure 1B; Table 1). Two
genome-wide significant loci were identified, themost significant
Table 1. Most Significant Associated Loci from SCZ versus BD GWAS
















P OR BD freq control
freq
P OR
rs56355601 1 173811455 T 0.7410 0.7230 5.7E-09 1.12 0.7340 0.7250 0.012 1.04 0.7220 0.7290 0.0449 0.96 1.74E-03
rs200005157 20 47638976 D 0.5300 0.5110 2.4E-08 1.10 0.5290 0.5190 0.004 1.04 0.5130 0.5220 0.0012 0.95 1.51E-05
rs10832027 11 13357183 A 0.6630 0.6840 6.8E-08 0.91 0.6610 0.6580 0.050 0.98 0.6840 0.6710 0.0004 1.06 6.86E-05
rs7823741 8 92904254 C 0.3720 0.3930 7.2E-08 0.91 0.3800 0.3880 0.115 0.98 0.3910 0.3840 0.0476 1.03 1.12E-02
rs7645466 3 50049958 T 0.4930 0.4760 7.8E-08 1.10 0.4990 0.5010 0.547 1.01 0.4800 0.4890 0.0018 0.95 5.01E-03
Association results for the five most significant variants in the SCZ versus BD GWAS, with the top two being genome-wide significant. Each variant
includes results from the independent BD versus controls and SCZ versus controls GWAS and the comparable p value from a heterogeneity test
when performing a two cohort meta-analysis of SCZ and BD.of which was rs56355601, located on chr1 at position
173,811,455 within an intron of DARS2 (Figure S1). The second
most significant locus was rs200005157, a four base-pair inser-
tion or deletion, on chr20 at position 47,638,976 in an intron of
ARFGEF2 (Figure S2). For both variants, the minor allele fre-
quency was higher in BD cases than SCZ cases, and disease-
specific GWAS showed opposite directions of effect when
compared to controls. We sought to identify additional dis-
ease-specific loci by comprehensively incorporating expression
information with association results to perform fine-mapping and
identify novel variants (Gamazon et al., 2015; Giambartolomei
et al., 2014; Gusev et al., 2016; He et al., 2013). Here, we applied
the summary-data-based Mendelian randomization (SMR)
method (Zhu et al., 2016) (see STAR Methods), utilizing the cis-
quantitative trait loci (QTLs) derived from peripheral blood
(Westra et al., 2013), human dorsolateral prefrontal cortex
(DLPFC) (Fromer et al., 2016) from the CommonMind Con-
sortium, and 11 brain regions from the GTEx consortium (The
GTEx Consortium, 2015). We identified one SNP-probe combi-
nation that surpassed the threshold for GWS in blood and was
also the most significant finding in brain. We found that SNP
rs4793172 in gene DCAKD is associated with SCZ versus BD
analysis (pGWAS = 2.8 3 10
6) and is an eQTL for probe ILMN
1811648 (peQTL = 2.9 3 10
168), resulting in pSMR = 4.1 3 10
6
in blood (peQTL = 2.93 10
25, pSMR = 2.03 10
5 in DLFC; peQTL =
4.6 3 1015, pSMR = 6.0 3 10
5 in GTEx cerebellar hemisphere)
(Figure S3; Table S3) and shows no evidence of heterogeneity
(pHET = 0.66), which implies only a single causal variant in
the locus.
In an effort to prioritize genes for the two GWS loci from the
GWAS, we performed fine-mapping (Benner et al., 2016) using
a linkage disequilibrium (LD) map derived from a majority of the
control samples. We then performed SMR on each of the vari-
ants with causal probability greater than 1% using all eQTLs
from the CommonMind Consortium DLPFC reference. All the
most likely causal variants were shown to most significantly
regulate the same gene, suggesting thatCSE1L is themost likely
relevant gene on chr20 (rs200005157: causal probability = 0.21,
pGWAS = 2.4 3 10
8, peQTL 3 3 10
8, pSMR = 8.5 3 10
5, pHET =
0.34). For the locus on chr1, SLC9C2 is the most significantly
regulated gene. However, a highly significant heterogeneity
test indicates a complex genetic architecture, making it difficultto infer a causal role for the associated SNP. Therefore, DARS2
presents as the most likely relevant gene on chr1 (rs56355601:
pGWAS = 5.6 3 10
9, causal probability = 0.079, peQTL 7.4 3
1013, pSMR = 6.17 3 10
6, pHET = 0.03). We note, however,
that in both cases there are variants that are stronger eQTLs
for these genes but not as significantly associated, complicating
a straightforward causal interpretation. Finally, using the same
gene-set test used for the combined analysis gene ontology
(GO) biological process ‘‘response to potassium ion’’ (p =
1.63 106) was the only pathway surpassing our Bonferroni cor-
rected significance threshold (Table S2b).
Regional Joint Association
We expanded our efforts to identify disorder-specific genomic
regions by jointly analyzing independent GWAS results from
BD and SCZ (Pickrell et al., 2016). The genome was split into
1,703 previously defined approximately LD-independent regions
(Berisa and Pickrell, 2016). 13%, or 223 regions, had a posterior
probability greater than 0.5 of having a causal variant for at least
one disorder. Of these, 132 best fit the model of a shared causal
variant influencing both BD and SCZ, 88weremost likely specific
to SCZ, 3 demonstrated evidence of two independent variants
(with one impacting each of the two disorders), and none were
BD specific. Of note, this approach calculates a prior probability
that any given region is disease specific and that, from these
data, the probability of having a BD-specific region was 0.1%
compared to 15% for SCZ, likely a result of increased power
from the larger SCZ sample size and/or a difference in genetic
architecture between these disorders.
The 114 GWS SNPs from the combined BD and SCZ GWAS
localized into 99 independent regions (13 regions had multiple
GWS SNPs), of which 78 (79%) were shared with a posterior
probability of greater than 0.5. Sixty regions had at least one
GWS SNP in the independent SCZ GWAS, of which 30 (50%)
are shared, and 8 regions contained a GWS SNP in the indepen-
dent BD GWAS, of which 6 (75%) are shared using the same
definition. For the three regions showing evidence for indepen-
dent variants, two had highly non-overlapping association sig-
nals in the same region stemming from independent variants.
The third, on chr19, presented a different scenario where asso-
ciation signals were overlapping. The most significant variant in
BD was rs111444407 (chr19:19358207, p = 8.67 3 1010) andCell 173, 1705–1715, June 14, 2018 1707
for SCZ was rs2315283 (chr19:19480575, p = 4.413 107). After
conditioning on the most significant variant in the other disorder,
the association signals of the most significant variant in BD and
SCZ were largely unchanged (BD rs111444407 = 1.3 3 109;
SCZ rs2315283 p = 6.73 105). We further calculated the prob-
ability of each variant in the region being causal for both BD and
SCZ (Benner et al., 2016) and found no correlation (r =
0.00016). The most significant variants had the highest poste-
rior probability of being causal (SCZ: rs2315283, prob = 0.02;
BD: rs111444407, prob = 0.16). Both variants most significantly
regulate the expression of GATAD2A in brain (Fromer et al.,
2016) but in opposite directions (rs111444407 peQTL = 6 3




Across the genome, regional SNP-heritabilities (h2snp) were
estimated separately for SCZ and BD (Shi et al., 2016) and
were found to be moderately correlated (r = 0.25). We next
defined risk regions as those containing the most-associated
SNP for each GWS locus. In total, there were 101 SCZ risk re-
gions from the 105 autosomal GWS loci reported previously
(Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014) and 29 BD risk regions from 30 GWS loci re-
ported previously (Stahl et al., 2017). Ten regions were risk re-
gions for both BD and SCZ, comprising 33% of BD risk regions
and 10% of SCZ risk regions. We further stratified regional
h2snp by whether a region was a risk region in one disorder,
none, or both (Figure S4). Since the discovery data for the re-
gions overlapped with the data used for the heritability estima-
tion, we expected within-disorder analyses to show significant
results. In risk regions specific to SCZ (n = 91), there was a sig-
nificant increase in regional h2snp in SCZ, as expected (p =
1.1 3 1022), but also in BD (p = 1.2 3 106). In the set of
risk regions specific to BD (n = 19), significantly increased
regional h2snp was observed in BD, as expected (p = 0.0007),
but not in SCZ (p = 0.89). Risk regions shared by both disorders
had significantly higher h2snp in both disorders, as expected
(BD p = 5.3 3 105; SCZ p = 0.006), compared to non-risk re-
gions. However, we observed a significant increase in BD h2snp
in shared risk regions compared to BD risk regions (BD p =
0.003) but not SCZ h2snp for shared risk regions compared to
SCZ risk regions (p = 0.62). Using a less stringent p value
threshold for defining risk regions (p < 5 3 106), thereby sub-
stantially increasing the number of regions, resulted in similar
results. Seven regions contributed to substantially higher
h2snp in SCZ compared to BD, but no region showed the in-
verse pattern. Of these regions, all but one was in the major
histocompatibility complex (MHC); the sole novel region was
chr10:104380410-106695047 with regional h2snp = 0.0019 in
SCZ and h2snp = 0.00063 in BD.
Polygenic Dissection of Subphenotypes
Subphenotypes were collected for a subset of patients with
either BD or SCZ (see STAR Methods). For SCZ, we had clinical
quantitative measurements of manic, depressive, positive, and
negative symptoms generated from factor analysis of multiple in-
struments as described previously (Ruderfer et al., 2014) but in1708 Cell 173, 1705–1715, June 14, 2018larger sample sizes (n = 6,908, 6,907, 8,259, and 8,355 respec-
tively). For BD, 24 subphenotypes were collected among nearly
13,000 cases in distinct categories including comorbidities, clin-
ical information such as rapid cycling and psychotic features,
and additional disease course data such as age of onset and
number of hospitalizations. For each BD or SCZ patient, we
calculated a PRS using all SNPs, from each of the four main
GWAS analyses (BD+SCZ, BD, SCZ, and SCZvsBD). We then
used regression analysis including principal components and
site to assess the relationship between each subphenotype
and the four PRSs. Specifically, we tested whether polygenic
risk scores of BD+SCZ, BD, SCZ, or SCZvsBD were correlated
with each of these subphenotypes separately within BD and
SCZ cases. When testing whether the variance explained by
the PRS was different from zero, we applied a significance cutoff
of p < 0.0004 based on Bonferroni correction for 112 tests. In to-
tal, we identified six significant results after correction (Figure 2;
Table 2).
A significant positive correlation existed between BD PRS and
manic symptoms in SCZ cases as seen previously (Ruderfer
et al., 2014) (p = 2 3 105, t = 4.26) and BD PRS and psychotic
features in BD patients (p = 5.33 105, t = 4.04). A significant in-
crease in SCZ PRS was seen for BD cases with versus without
psychotic features (p = 1.2 3 1010, t = 6.45) and SCZ patients
with increased negative symptoms (p = 3.60 3 106, t = 4.64).
The BD+SCZ versus controls PRS was significantly associated
with psychotic features in BD (p = 7.9 3 1013, t = 7.17) and
negative symptoms in SCZ (p = 1.5 3 105, t = 4.33). The next
two most significant results that did not survive our conservative
correction were both indicative of a more severe course in BD:
increased BD+SCZ PRS with increased numbers of hospitaliza-
tions in BD cases (p = 4.2 3 104, t = 3.53) and increased SCZ
PRS with earlier onset of BD (p = 7.9 3 104, t = 3.36). We as-
sessed the role of BD subtype on the correlation between SCZ
PRS and psychotic features and identified a significant correla-
tion when restricted to only BD type I cases, indicating that
the result was not likely driven by BD patients with a schizoaffec-
tive subtype (BDI: 3,763 with psychosis, 2,629 without, p =
1.55 3105; Table S4).
We performed a GWAS for all eight quantitative subpheno-
types and nine binary subphenotypes with at least 1,000 cases
and calculated heritability and genetic correlation with BD and
SCZ. Only two subphenotypes had significant h2snp estimates
using LD-score regression (Bulik-Sullivan et al., 2015), both in
BD: psychotic features in BD (h2snp = 0.15, SE = 0.06) and suicide
attempt (h2snp = 0.25, SE = 0.1). Only psychotic features demon-
strated a significant genetic correlation with SCZ (rg = 0.34, SE =
0.13, p = 0.009). The significant genetic correlation demon-
strates a genome-wide relationship between common variants
contributing to SCZ risk and those contributing to psychotic fea-
tures in BD cases. We tested whether the most significantly
associated SCZ loci contributed directly to psychotic features
in BD. One hundred of the 105 autosomal genome-wide signifi-
cant SCZ SNPs previously published (Schizophrenia Working
Group of the Psychiatric Genomics Consortium, 2014) were in
our dataset after quality control, and 60 were in the same direc-
tion of effect for risk of psychotic features in BD (p = 0.028, one-
sided binomial-test).
Figure 2. Polygenic Risk Score Dissection of
Clinical Symptom Dimensions
Effect size (calculated by dividing regression esti-
mate by standard error) from regression analysis
including ancestry covariates for each sub-
phenotype and PRS for BD (x axis) and SCZ (y axis).
Point size represents –log10(p value) with SCZ (red)
and BD (blue). Numbered subphenotypes are (1)
comorbid migraine, (2) panic attacks, (3) suicide
attempt, (4) mixed states, (5) rapid cycling, (6) co-
morbid eating disorder, (7) comorbid OCD, (8) year
of birth, (9) suicide ideation, (10) panic disorder,
(11) number of suicide attempts, (12) depressive
symptoms (SCZ), (13) episodes depressive, (14)
episodes total, (15) positive symptoms (SCZ), (16)
irritable mania, (17) age of onset depression, (18)
family history, (19) episodes mixed mania, (20)
unipolar mania, (21) alcohol substance depen-
dence, (22) age of onset mania, (23) age at inter-
view, and (24) number of hospitalizations. All sub-
phenotypes are in BD except those labeled SCZ.DISCUSSION
Here, we present a genetic dissection of bipolar disorder and
schizophrenia from over 100,000 genotyped subjects. Consis-
tent with earlier results (Lee et al., 2013), we found extensive ge-
netic sharing between these two disorders, identifying 114 GWS
loci contributing to both disorders, of which 32 are novel. These
findings point to the relevance of neuronal and synaptic biology
for the shared genetic substrate of these disorders. However,
despite this degree of sharing, we identified several loci that
significantly differentiated between the two disorders, having
opposite directions of effect. We also found polygenic compo-
nents that significantly correlated from one disorder to symp-
toms of the other.
Two GWS loci were identified from the case-only SCZ versus
BD analysis, providing opportunities to inform the underlying
biological distinctions between BD and SCZ. The most signifi-
cant locus implicates DARS2 (coding for the mitochondrial
Aspartate-tRNA ligase), which is highly expressed in the
brain and significantly regulated by the most significant SNP,
rs56355601 (peQTL = 2.5 3 10
11). Homozygous mutations in
DARS2 are responsible for leukoencephalopathy with brainstem
and spinal cord involvement and lactate elevation (LBSL), which
was characterized by neurological symptoms such as psy-
chomotor developmental delay, cerebellar ataxia, and delayed
mental development (Yamashita et al., 2013, p. 2). Based on
methylation analysis from the prefrontal cortex of stress models(rats and monkeys) and from peripheral
samples (in monkeys and human new-
borns), DARS2, among others, has been
suggested as a potential molecular marker
of early life stress and vulnerability to psy-
chiatric disorders (Luoni et al., 2016). The
second most significant locus implicates
CSE1L, a nuclear transport factor that
plays a role in cellular proliferation as well
as in apoptosis (Bera et al., 2001). IntronicSNPs inCSE1L have been associated with subjective well-being
(Okbay et al., 2016) and nominally to antidepressant response (Li
et al., 2016). More interestingly, CSE1L is a potential target gene
of miR-137, one of the well-known schizophrenia risk loci
(Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014), which is able to negatively regulate CSE1L
by interacting with complementary sequences in the 30 UTR of
CSE1L (Li et al., 2013). Although falling short of genome-wide
significance, the third most significant locus implicates ARNTL
(aryl hydrocarbon receptor nuclear translocator like), which is a
core component of the circadian clock. ARNTL has been previ-
ously hypothesized for relevance in bipolar disorder (Yang
et al., 2009), although human genetic evidence is currently
limited (Byrne et al., 2014).
The ability to generate transcriptional data on multiple tissues
across many individuals using RNA sequencing has provided
detailed information on the role common variants play in regu-
lating expression of specific genes in specific tissues. These
eQTLs can be integrated with the genetic association data
from GWAS to inform on the relationship between variant asso-
ciation and variant regulation of expression for each gene. Per-
forming this integration, we identified a third GWS finding in
DCAKD. The gene codes for dephospho-CoA kinase domain
containing protein, a member of the human postsynaptic density
proteome from human neocortex (Bayés et al., 2011). In the
mouse cortical synaptoproteome, DCAKD is among the proteins
with the highest changes between juvenile postnatal days andCell 173, 1705–1715, June 14, 2018 1709
Table 2. Complete Results of Polygenic Risk Score Dissection Analysis
Disorder Subphenotype N Cases Controls P value Effect
BD+SCZ BD SCZ SCZvsBD BD+SCZ BD SCZ SCZvsBD
BD psychosis 8131 4632 3499 7.9E-13 5.3E-05 1.2E-10 5.8E-01 7.17 4.04 6.45 0.55
suicide ideation 5399 3801 1598 7.8E-01 1.8E-01 8.7E-01 1.7E-01 0.28 1.35 0.16 1.37
family history 4971 2730 2241 6.1E-02 2.8E-01 2.6E-01 6.9E-01 1.87 1.09 1.13 0.39
irritable mania 4230 2401 1829 3.8E-01 4.1E-01 7.1E-01 1.0E-01 0.88 0.83 0.38 1.63
rapid cycling 5214 1744 3470 7.9E-03 5.1E-02 5.5E-02 3.1E-01 2.66 1.95 1.92 1.01
alcohol substance
dependence
5440 1494 3946 4.5E-01 2.1E-01 2.8E-02 1.7E-01 0.75 1.25 2.20 1.36
panic disorder 4647 863 3784 2.8E-01 1.8E-01 6.3E-01 4.0E-01 1.07 1.33 0.49 0.83
panic attacks 3976 851 3125 1.3E-01 1.1E-02 9.0E-01 4.7E-02 1.50 2.56 0.13 1.98
mixed states 4044 826 3218 1.0E-01 4.2E-02 4.8E-01 6.0E-02 1.64 2.03 0.71 1.88
unipolar mania 4863 461 4402 2.4E-02 2.5E-01 4.3E-01 6.1E-01 2.26 1.14 0.78 0.51
comorbid migraine 2652 410 2242 1.3E-02 1.2E-03 7.2E-01 4.4E-01 2.48 3.23 0.36 0.77
comorbid OCD 4215 386 3829 9.7E-01 1.0E-01 3.1E-01 1.9E-01 0.04 1.64 1.02 1.30
comorbid eating disorder 3839 331 3508 2.1E-01 6.7E-02 8.1E-01 6.3E-01 1.25 1.83 0.24 0.48
suicide attempt 6308 2412 3896 1.2E-01 1.4E-02 5.3E-01 2.8E-01 1.54 2.45 0.63 1.09
age of onset 8610 6.2E-03 9.3E-01 7.9E-04 6.2E-01 2.74 0.09 3.36 0.50
age at interview 8062 5.9E-01 1.9E-02 5.7E-01 4.4E-01 0.54 2.35 0.57 0.78
episodes mixed mania 6587 6.3E-01 2.6E-01 5.6E-01 3.2E-01 0.48 1.13 0.58 1.00
episodes depressive 6252 7.4E-03 7.6E-01 1.6E-02 9.6E-01 2.68 0.31 2.42 0.05
episodes total 5958 1.3E-01 8.9E-01 2.6E-01 3.9E-01 1.51 0.14 1.13 0.87
year of birth 5317 1.7E-01 1.3E-01 4.0E-02 3.6E-02 1.39 1.53 2.05 2.10
number of suicide attempts 5015 6.2E-02 1.9E-01 2.7E-01 4.9E-01 1.87 1.30 1.10 0.69
number of hospitalizations 3944 4.2E-04 1.5E-02 2.5E-02 7.4E-01 3.53 2.43 2.25 0.33
age of onset depression 3467 2.3E-01 4.0E-01 7.2E-02 2.2E-01 1.19 0.83 1.80 1.24
age of onset mania 3395 2.5E-01 6.1E-02 1.9E-02 2.2E-01 1.14 1.87 2.35 1.23
SCZ Manic 6908 2.4E-02 2.0E-05 9.9E-01 3.5E-02 2.26 4.26 0.01 2.10
Depressive 6907 9.0E-01 5.7E-01 7.4E-01 1.8E-01 0.13 0.57 0.33 1.36
Negative 8355 1.5E-05 2.9E-01 3.6E-06 2.1E-02 4.33 1.06 4.64 2.31
Positive 8259 4.1E-01 9.9E-01 3.7E-01 5.1E-01 0.82 0.01 0.89 0.65
Polygenic scoring results of all four GWASphenotypes (BD+SCZ versus controls, BD versus controls, SCZ versus controls, and SCZ versus BD) and 24
subphenotypes from BD and 4 subphenotypes from SCZ, rows without case/control counts are quantitative measures. Significance and effects are
from regression analysis of subphenotype on PRS including principal components of ancestry and site as covariates. Effect is the regression estimate
divided by the standard error. p values in bold are significant after correction.adult stage, suggesting a putative role in brain development
(Gonzalez-Lozano et al., 2016; Moczulska et al., 2014).
Discerning between pleiotropy (variant independently regulates
expression and alters risk to disease) from causality (variant reg-
ulates expression, which thereby alters risk to disease) through
statistical analysis alone is difficult; this analytical approach
is stringent in excluding loci where co-localized SNP-phenotype
and SNP-expression associations may reflect confounding
driven by LD (one variant regulates expression and a different
variant alters risk, but the variants in the region are in LD). Hence,
this approach utilizes currently available data to prioritize genes,
including direction of effect, for functional follow-up. These ana-
lyses will become more powered with increased sample sizes
for both phenotype and eQTL datasets.
Performing pathway analysis based on the full association re-
sults shows enrichment of genes involved in response to potas-1710 Cell 173, 1705–1715, June 14, 2018sium ions, including potassium voltage-gated channel subfamily
members and a number of genes regulated by cellular potassium
concentration. This is in line with previous genetic evidence
pointing to a key etiologic role of potassium channels, in partic-
ular, in BD (Judy and Zandi, 2013), which could be explained
by their role in multiple neurobiological mechanisms involved in
the development of psychiatric disorders such as regulation of
the dopaminergic circuits, synaptic plasticity, and myelination
(Balaraman et al., 2015).
We further assessed the contribution of regions of the
genome to each disorder through joint regional association
and heritability estimation. These results point to an additional
locus that may contribute differentially to liability to BD and
SCZ. The region on chr19 shows overlapping association peaks
that are driven by independent causal variants for each disorder.
Both variants significantly regulate the same gene, GATAD2A,
but in opposite directions. GATAD2A is a transcriptional
repressor, which is targeted byMBD2 and is involved in methyl-
ation-dependent gene silencing. The protein is part of the large
NuRD (nucleosome remodeling and deacetylase) complex, for
which HDAC1/2 are essential components. NurD complex pro-
teins have been associated with autism (Li et al., 2015). Their
members, including GATAD2A, display preferential expression
in fetal brain development (Li et al., 2015) and in recent work
have been implicated in SCZ through open chromatin (Fullard
et al., 2017). Further, p66a (mouse GATAD2A) was recently
shown to participate in memory preservation through long-last-
ing histone modification in hippocampal memory-activated neu-
rons (Ding et al., 2017). SNP-heritability appears to be consis-
tently shared across regions and chromosomes between
these two disorders. Regions with GWS loci often explain higher
proportions of heritability, as expected. When looking at the ef-
fect on heritability of the presence of a GWS locus in the other
disorder, we identified a significant increase in BD heritability
for regions containing a GWS locus for SCZ but no significant
increase in SCZ heritability in regions having a BD one. This
result suggests a directionality to the genetic sharing of these
disorders, with a larger proportion of BD loci being specific to
BD. However, we cannot exclude that the asymmetry of results
may reflect less power of discovery for BD than SCZ. The de-
gree to which power and subphenotypes contribute to this
result requires further examination.
We note that, as with nearly all GWAS findings, the calculated
population-based effect sizes of the variants identified here are
small and independently explain only a modest fraction to the
heritability of these disorders. The identification of these variants
is dependent on the ability to have highly accurate allele-fre-
quency estimates that can only be ascertained from large sam-
ple sizes. As sample sizes get larger, the power to identify
variants of smaller effect increases, meaning that increasing
sample size results in the identification of variants of smaller ef-
fect. However, a small population effect size does not exclude
the possibility of a substantially larger effect on molecular phe-
notypes nor does it preclude the utility of association regions
in understanding biology or having a clinical impact. Efforts
following up GWAS results to date have demonstrated the value
of these findings in pointing to genes that can aid in understand-
ing the underlying biology of the trait (Claussnitzer et al., 2015;
Mohanan et al., 2018; Sekar et al., 2016). Further, there is a clear
relationship between GWAS results of a phenotype and gene
targets of drugs that treat that phenotype, pointing to the poten-
tial for improved therapeutic understanding (Nelson et al., 2015;
Ruderfer et al., 2016). A major challenge of GWAS is the sheer
number of findings and the substantial time and/or cost required
for functional follow-up of these findings in the classical para-
digms used for genes causal for monogenic disorders. In silico
bioinformatic analyses (such as SMR used here) that integrate
GWAS results with omics data (transcription, protein, epige-
netic, etc.) have the potential to put a clearer biological focus
on GWAS results. Such analyses can become more complex
as more reference omics datasets (with genome-wide genotyp-
ing) become available. Additional analytical efforts will be
required to facilitate the transition from GWAS to biology, but
substantial data has shown that there is much to be learnedfrom these variants despite their small effects (Visscher
et al., 2017).
Wehavenow identifiedmultiple genomic signatures that corre-
late between one disorder and a clinical symptom in the other
disorder, illustrating genetic components underlying particular
symptomdimensionswithin thesedisorders.Medical symptoms,
including those seen in psychiatric disorders, can manifest
through a multitude of causes. The classic example often used
is headache, for which many different paths lead to the same
symptom. Psychiatric symptoms also have many potential
causes. For example, symptoms of psychosis can be the result
of highly heritable diseases such as BD and SCZ but also infec-
tious and neurodegenerative diseases, sleep and/or sensory
deprivation, or psychedelic drugs. Demonstrating a shared bio-
logical underpinning to these symptoms suggests that they could
be treated through modulating the same pathway. As previously
shown,we find a significant positive correlation between the PRS
ofBDandmanic symptoms inSCZ.Wealsodemonstrate thatBD
cases with psychotic features carry a significantly higher SCZ
PRS thanBDcaseswithout psychotic features and that this result
is not driven by the schizoaffective BD subtype. Further, we show
that increased PRS is associated withmore severe illness. This is
true for BD with psychotic features having increased SCZ PRS,
earlier onset BD having higher SCZ PRS, and cases with higher
BD+SCZ PRS having a larger number of hospitalizations. We
demonstrated that psychotic featureswithinBD is a heritable trait
and that GWS loci for SCZ have a consistent direction of effect in
psychotic features in BD, demonstrating the potential to study
psychosis more directly to identify variants contributing to that
symptom dimension.
This work illustrates the utility of genetic data, in aggregate, at
dissecting symptom heterogeneity among related disorders and
suggests that further work could aid in characterizing patients
for more personalized treatment. Genetic risk scores have
demonstrated their ability to inform and predict pathology (Cley-
nen et al., 2016) and more recently have been shown to be able
to identify patients with risk equivalent to monogenic variants
(Khera et al., 2017). In psychiatry, we lack objective biological
measurements (biomarkers) with which to assess the ability of
a genetic signature to predict or inform. Lacking diagnostic pa-
thology for psychiatric disorders leaves a genuine opportunity
for the genetics to drive diagnosis and treatment to a much
larger degree than in other domains. One potential model as-
sumes that each individual has a quantitative loading of a series
of symptom dimensions (i.e., manic, psychotic, cognitive, etc.)
and that these symptoms can be assessed at the genetic level
to characterize a patient’s dysfunction and used to inform dis-
ease course and optimal treatment. Making this a reality will
require more detailed information on disease course and out-
comes. For example, if treatment response data existed for
these samples, one could ask whether a genetic loading for psy-
chosis was correlated with response to treatment. Initial work
has already shown the potential of this approach using a SCZ
PRS to inform lithium response in BD (Amare et al., 2018). Ulti-
mately, the goal will be to quantify multiple genetic loadings of
each individual’s illness and use those measures in concert
with clinical data to inform treatment based on the outcomes
of previous individuals with similar profiles.Cell 173, 1705–1715, June 14, 2018 1711
In conclusion, we present a detailed genetic dissection of BD
and SCZ, pointing to substantial shared genetic risk but also
demonstrating that specific loci contribute to the phenotypic dif-
ferences of these disorders. We show that genetic risk scores
can correspond to symptoms within and across disorders.
Finally, we present data that points to these disorders being
neither independent nor the same but sharing particular symp-
tom dimensions that can be captured from the genetics and
used to characterize patients to ultimately inform diagnosis
and treatment.
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A. Nwulia, Eadbhard O’Callaghan, Claire O’Donovan, Colm O’Dushlaine, F.
Anthony O’Neill, Ketil J. Oedegaard, Sang-Yun Oh, Ann Olincy, Line Olsen, Lil-
ijana Oruc, Jim Van Os, Michael J. Owen, Sara A. Paciga, Colin N.A. Palmer,
Aarno Palotie, Christos Pantelis, George N. Papadimitriou, Elena Parkho-
menko, Carlos Pato, Michele T. Pato, Tiina Paunio, Richard Pearson, Psycho-
sis Endophenotypes International Consortium, Diana O. Perkins, Roy H. Perlis,
Amy Perry, Tune H. Pers, Tracey L. Petryshen, Andrea Pfennig, Marco Pic-
chioni, Olli Pietilainen, Jonathan Pimm, Matti Pirinen, Robert Plomin, Andrew
J. Pocklington, Danielle Posthuma, James B. Potash, Simon C. Potter, John
Powell, Alkes Price, Ann E. Pulver, Shaun M. Purcell, Digby Quested, Josep
Antoni Ramos-Quiroga, Henrik B. Rasmussen, Anna Rautanen, Radhi Ravin-
drarajah, Eline J. Regeer, Abraham Reichenberg, Andreas Reif, Mark A. Reim-
ers, Marta Ribases, John P. Rice, Alexander L. Richards, Michelle Ricketts,
Brien P. Riley, Fabio Rivas, Margarita Rivera, Joshua L. Roffman, Guy A.
Rouleau, Panos Roussos, Dan Rujescu, Veikko Salomaa, Cristina Sanchez-
Mora, Alan R. Sanders, Stephen J. Sawcer, Ulrich Schall, Alan F. Schatzberg,
William A. Scheftner, Peter R. Schofield, Nicholas J. Schork, Sibylle G.
Schwab, Edward M. Scolnick, Laura J. Scott, Rodney J. Scott, Larry J. Seid-
man, Alessandro Serretti, Pak C. Sham, Cynthia Shannon Weickert, Tatyana
Shehktman, Jianxin Shi, Paul D. Shilling, Engilbert Sigurdsson, Jeremy M. Sil-
verman, Kang Sim, Claire Slaney, Petr Slominsky, Olav B. Smeland, JordanW.
Smoller, Hon-Cheong So, Janet L. Sobell, Erik Soderman, Christine Soholm
Hansen, Chris C.A. Spencer, Anne T. Spijker, David St Clair, Hreinn Stefans-
son, Kari Stefansson, Stacy Steinberg, Elisabeth Stogmann, Eystein Stordal,
Amy Strange, Richard E. Straub, John S. Strauss, Fabian Streit, Eric Streng-
man, Jana Strohmaier, T. Scott Stroup, Zhan Su, Mythily Subramaniam, Jaana
Suvisaari, Dragan M. Svrakic, Jin P. Szatkiewicz, Szabolcs Szelinger, Avazeh
Tashakkori-Ghanbaria, Srinivas Thirumalai, Robert C. Thompson, Thorgeir E.
Thorgeirsson, Draga Toncheva, Paul A. Tooney, Sarah Tosato, Timothea Tou-
lopoulou, Richard C. Trembath, Jens Treutlein, Vassily Trubetskoy, Gustavo
Turecki, Arne E. Vaaler, Helmut Vedder, Eduard Vieta, John Vincent, Peter
M. Visscher, Ananth C. Viswanathan, Damjan Vukcevic, John Waddington,
Matthew Waller, Dermot Walsh, Muriel Walshe, James T.R. Walters, Dai
Wang, QiangWang, Weiqing Wang, YunpengWang, Stanley J. Watson, Brad-
ley T. Webb, Thomas W. Weickert, Daniel R. Weinberger, Matthias Weisbrod,
Mark Weiser, Thomas Werge, Paul Weston, Pamela Whittaker, Sara Widaa,
Durk Wiersma, Dieter B. Wildenauer, Nigel M. Williams, Stephanie Williams,
Stephanie H. Witt, Aaron R. Wolen, Emily H.M. Wong, Nicholas W. Wood,
Brandon K. Wormley, Wellcome Trust Case-Control Consortium, Jing Qin
Wu, Simon Xi, Wei Xu, Allan H. Young, Clement C. Zai, Peter Zandi,
Peng Zhang, Xuebin Zheng, Fritz Zimprich, Sebastian Zollner, Aiden Corvin,
AymanH. Fanous, Sven Cichon, Marcella Rietschel, Elliot S. Gershon, Thomas
G. Schulze, Alfredo B. Cuellar-Barboza, Andreas J. Forstner, Peter A.
Holmans, John I. Nurnberger, Ole A. Andreassen, S. Hong Lee, Michael C.
O’Donovan, Patrick F. Sullivan, Roel A. Ophoff, Naomi R. Wray, Pamela Sklar,
Kenneth S. Kendler
ACKNOWLEDGMENTS
The work of the contributing groups was supported by numerous
grants from governmental and charitable bodies as well as philanthropic
donation. Specifically, D.M.R. (R01MH111776) and N.R.W. (NHMRC
1078901, 1087889).
AUTHOR CONTRIBUTIONS
D.M.R., P.S., and K.S.K. managed and organized the group. D.M.R., S.R.,
J.B., E.A.S., J.M.W.P., N.M., A.W.C., A.P.S.O., L.M.O.L., and V.T. contributed
to analyses. Subphenotype collection and organization was led by A.M. and
A.H.F. Initial manuscript was drafted by D.M.R., E.D., A.D.F., S.P., J.L.K.
Manuscript contributions and interpretation of results were provided by
D.M.R., E.D., S.H.L., M.C.O., P.F.S., R.A.O., N.R.W., P.S., and K.S.K. The re-
maining authors contributed to the recruitment, genotyping, or data process-
ing for the contributing components of the study. All other authors saw, had the
opportunity to comment on, and approved the final draft.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: August 16, 2017
Revised: March 13, 2018
Accepted: May 21, 2018
Published: June 14, 2018REFERENCES
Amare, A.T., Schubert, K.O., Hou, L., Clark, S.R., Papiol, S., Heilbronner, U.,
Degenhardt, F., Tekola-Ayele, F., Hsu, Y.-H., Shekhtman, T., et al.; Interna-
tional Consortium on Lithium Genetics (ConLi+Gen) (2018). Association of
polygenic score for schizophrenia and HLA antigen and inflammation genes
with response to lithium in bipolar affective disorder: a genome-wide associa-
tion study. JAMA Psychiatry 75, 65–74.
Balaraman, Y., Lahiri, D.K., and Nurnberger, J.I. (2015). Variants in ion channel
genes link phenotypic features of bipolar illness to specific neurobiological
process domains. Mol. Neuropsychiatry 1, 23–35.
Bayés, A., van de Lagemaat, L.N., Collins, M.O., Croning, M.D.R., Whittle, I.R.,
Choudhary, J.S., and Grant, S.G.N. (2011). Characterization of the proteome,
diseases and evolution of the human postsynaptic density. Nat. Neurosci.
14, 19–21.
Benner, C., Spencer, C.C.A., Havulinna, A.S., Salomaa, V., Ripatti, S., and Pir-
inen, M. (2016). FINEMAP: efficient variable selection using summary data
from genome-wide association studies. Bioinformatics 32, 1493–1501.
Bera, T.K., Bera, J., Brinkmann, U., Tessarollo, L., and Pastan, I. (2001). Cse1l
is essential for early embryonic growth and development. Mol. Cell. Biol. 21,
7020–7024.
Berisa, T., and Pickrell, J.K. (2016). Approximately independent linkage
disequilibrium blocks in human populations. Bioinformatics 32, 283–285.
Bulik-Sullivan, B.K., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Schizo-
phrenia Working Group of the Psychiatric Genomics Consortium, Patterson,
N., Daly, M.J., Price, A.L., and Neale, B.M. (2015). LD Score regression distin-
guishes confounding from polygenicity in genome-wide association studies.
Nat. Genet 47, 291–295.
Byrne, E.M., Heath, A.C., Madden, P.A., Pergadia, M.L., Hickie, I.B., Mont-
gomery, G.W., Martin, N.G., and Wray, N.R. (2014). Testing the role of circa-
dian genes in conferring risk for psychiatric disorders. Am. J. Med. Genet.
Part B Neuropsychiatr. Genet 165, 254–260.
Claussnitzer, M., Dankel, S.N., Kim, K.-H., Quon, G., Meuleman, W., Haugen,
C., Glunk, V., Sousa, I.S., Beaudry, J.L., Puviindran, V., et al. (2015). FTO
obesity variant circuitry and adipocyte browning in humans. N. Engl. J. Med.
373, 895–907.
Cleynen, I., Boucher, G., Jostins, L., Schumm, L.P., Zeissig, S., Ahmad, T., An-
dersen, V., Andrews, J.M., Annese, V., Brand, S., et al. (2016). Inherited deter-
minants of Crohn’s disease and ulcerative colitis phenotypes: a genetic asso-
ciation study. Lancet 387, 156–167.
Marshall, C.R., Howrigan, D.P., Merico, D., Thiruvahindrapuram, B., Wu, W.,
Greer, D.S., Antaki, D., Shetty, A., Holmans, P.A., Pinto, D., et al.; Psychosis
Endophenotypes International Consortium; CNV and Schizophrenia Working
Groups of the Psychiatric Genomics Consortium (2017). Contribution of
copy number variants to schizophrenia from a genome-wide study of 41,321
subjects. Nat. Genet. 49, 27–35.
The GTEx Consortium (2015). The Genotype-Tissue Expression (GTEx) pilot
analysis: Multitissue gene regulation in humans. Science 348, 648–660.
Curtis, D., Vine, A.E., McQuillin, A., Bass, N.J., Pereira, A., Kandaswamy, R.,
Lawrence, J., Anjorin, A., Choudhury, K., Datta, S.R., et al. (2011). Case-
case genome-wide association analysis shows markers differentially associ-
ated with schizophrenia and bipolar disorder and implicates calcium channel
genes. Psychiatr. Genet. 21, 1–4.
de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA:
generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11,
e1004219.
Delaneau, O., Zagury, J.-F., and Marchini, J. (2013). Improved whole-chromo-
some phasing for disease and population genetic studies. Nat. Methods
10, 5–6.
Ding, X., Liu, S., Tian, M., Zhang, W., Zhu, T., Li, D., Wu, J., Deng, H., Jia, Y.,
Xie, W., et al. (2017). Activity-induced histonemodifications govern Neurexin-1
mRNA splicing and memory preservation. Nat. Neurosci. 20, 690–699.Cell 173, 1705–1715, June 14, 2018 1713
DSM Library. Diagnostic and Statistical Manual of Mental Disorders. http://
dsm.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596.
Fromer, M., Pocklington, A.J., Kavanagh, D.H., Williams, H.J., Dwyer, S.,
Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D.M., et al. (2014).
De novo mutations in schizophrenia implicate synaptic networks. Nature
506, 179–184.
Fromer, M., Roussos, P., Sieberts, S.K., Johnson, J.S., Kavanagh, D.H., Peru-
mal, T.M., Ruderfer, D.M., Oh, E.C., Topol, A., Shah, H.R., et al. (2016). Gene
expression elucidates functional impact of polygenic risk for schizophrenia.
Nat. Neurosci. 19, 1442–1453.
Fullard, J.F., Giambartolomei, C., Hauberg, M.E., Xu, K., Voloudakis, G., Shao,
Z., Bare, C., Dudley, J.T., Mattheisen, M., Robakis, N.K., et al. (2017). Open
chromatin profiling of human postmortem brain infers functional roles for
non-coding schizophrenia loci. Hum. Mol. Genet 26, 1942–1951.
Gamazon, E.R., Wheeler, H.E., Shah, K.P., Mozaffari, S.V., Aquino-Michaels,
K., Carroll, R.J., Eyler, A.E., Denny, J.C., GTEx Consortium, Nicolae, D.L.,
Cox, N.J., and Im, H.K. (2015). A gene-based association method for mapping
traits using reference transcriptome data. Nat. Genet 47, 1091–1098.
Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D.,
Wallace, C., and Plagnol, V. (2014). Bayesian test for colocalisation between
pairs of genetic association studies using summary statistics. PLoS Genet.
10, e1004383.
Gonzalez-Lozano, M.A., Klemmer, P., Gebuis, T., Hassan, C., van Nierop, P.,
van Kesteren, R.E., Smit, A.B., and Li, K.W. (2016). Dynamics of the mouse
brain cortical synaptic proteome during postnatal brain development. Sci.
Rep. 6 https://doi.org/10.1038/srep35456.
Green, E.K., Rees, E., Walters, J.T.R., Smith, K.-G., Forty, L., Grozeva, D.,
Moran, J.L., Sklar, P., Ripke, S., Chambert, K.D., et al. (2016). Copy number
variation in bipolar disorder. Mol. Psychiatry 21, 89–93.
Gulsuner, S., and McClellan, J.M. (2015). Copy number variation in schizo-
phrenia. Neuropsychopharmacology 40, 252–254.
Gusev, A., Ko, A., Shi, H., Bhatia, G., Chung, W., Penninx, B.W.J.H., Jansen,
R., de Geus, E.J.C., Boomsma, D.I., Wright, F.A., et al. (2016). Integrative ap-
proaches for large-scale transcriptome-wide association studies. Nat. Genet.
48, 245–252.
He, X., Fuller, C.K., Song, Y., Meng, Q., Zhang, B., Yang, X., and Li, H. (2013).
Sherlock: detecting gene-disease associations by matching patterns of
expression QTL and GWAS. Am. J. Hum. Genet. 92, 667–680.
Howie, B., Marchini, J., and Stephens, M. (2011). Genotype imputation with
thousands of genomes. G3: Genes, Genomes, Genetics 1, 457–470.
Judy, J.T., and Zandi, P.P. (2013). A review of potassium channels in bipolar
disorder. Front. Genet. 4 https://doi.org/10.3389/fgene.2013.00105.
Kataoka, M., Matoba, N., Sawada, T., Kazuno, A.-A., Ishiwata, M., Fujii, K.,
Matsuo, K., Takata, A., and Kato, T. (2016). Exome sequencing for bipolar dis-
order points to roles of de novo loss-of-function and protein-altering muta-
tions. Mol. Psychiatry 21, 885–893.
Khera, A.V., Chaffin, M., Aragam, K., Emdin, C.A., Klarin, D., Haas, M., Roselli,
C., Natarajan, P., and Kathiresan, S. (2017). Genome-wide polygenic score to
identify amonogenic risk-equivalent for coronary disease. bioRxiv. https://doi.
org/10.1101/218388.
Kirov, G., Pocklington, A.J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D.,
Moran, J., Chambert, K., Toncheva, D., Georgieva, L., et al. (2012). De novo
CNV analysis implicates specific abnormalities of postsynaptic signalling com-
plexes in the pathogenesis of schizophrenia. Mol. Psychiatry 17, 142–153.
Lee, S.H., Ripke, S., Neale, B.M., Faraone, S.V., Purcell, S.M., Perlis, R.H.,
Mowry, B.J., Thapar, A., Goddard, M.E., Witte, J.S., et al.; Cross-Disorder
Group of the Psychiatric Genomics Consortium; International Inflammatory
Bowel Disease Genetics Consortium (IIBDGC) (2013). Genetic relationship be-
tween five psychiatric disorders estimated from genome-wide SNPs. Nat.
Genet. 45, 984–994.
Li, K.K.-W., Yang, L., Pang, J.C.-S., Chan, A.K.-Y., Zhou, L.,Mao, Y., Wang, Y.,
Lau, K.-M., Poon, W.S., Shi, Z., and Ng, H.-K. (2013). MIR-137 suppresses1714 Cell 173, 1705–1715, June 14, 2018growth and invasion, is downregulated in oligodendroglial tumors and targets
CSE1L. Brain Pathol. 23, 426–439.
Li, J., Ma, Z., Shi, M., Malty, R.H., Aoki, H., Minic, Z., Phanse, S., Jin, K., Wall,
D.P., Zhang, Z., et al. (2015). Identification of human neuronal protein com-
plexes reveals biochemical activities and convergent mechanisms of action
in autism spectrum disorders. Cell Syst. 1, 361–374.
Li, Q.S., Tian, C., Seabrook, G.R., Drevets, W.C., and Narayan, V.A. (2016).
Analysis of 23andMe antidepressant efficacy survey data: implication of circa-
dian rhythm and neuroplasticity in bupropion response. Transl. Psychiatry
6, e889.
Lichtenstein, P., Yip, B.H., Björk, C., Pawitan, Y., Cannon, T.D., Sullivan, P.F.,
and Hultman, C.M. (2009). Common genetic determinants of schizophrenia
and bipolar disorder in Swedish families: a population-based study. Lancet
373, 234–239.
Luoni, A., Massart, R., Nieratschker, V., Nemoda, Z., Blasi, G., Gilles, M., Witt,
S.H., Suderman, M.J., Suomi, S.J., Porcelli, A., et al. (2016). Ankyrin-3 as amo-
lecular marker of early-life stress and vulnerability to psychiatric disorders.
Transl. Psychiatry 6, e943.
Moczulska, K.E., Pichler, P., Schutzbier, M., Schleiffer, A., Rumpel, S., and
Mechtler, K. (2014). Deep and precise quantification of the mouse synapto-
somal proteome reveals substantial remodeling during postnatal maturation.
J. Proteome Res. 13, 4310–4324.
Mohanan, V., Nakata, T., Desch, A.N., Lévesque, C., Boroughs, A., Guzman,
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Genotyped Sample Description
SCZ samples are a substantial subset of those analyzed previously (Schizophrenia Working Group of the Psychiatric Genomics Con-
sortium, 2014). BD samples are the newest collection from Psychiatric Genomics Consortium Bipolar Disorder Working Group (Stahl
et al., 2017).
Below we provide information on the individual samples used here as provided by the original PGC disorder publications. Addi-
tionally, most studies have been described in detail in the citations provided. The boldfaced first line for each sample is study PI,
PubMed ID, country (study name), and the PGC internal tag or study identifier.
European ancestry, case-control design
Schizophrenia
Adolfsson, R j NP j Umeå, Sweden j scz_umeb_eur
Adolfsson, R j NP j Umeå, Sweden j scz_umes_eur
Cases of European ancestry were ascertained from multiple different studies of schizophrenia (1992-2009). The diagnostic pro-
cesses were similar between studies, and the final diagnosis is a best-estimate consensus lifetime diagnosis based onmultiple sour-
ces of information such as clinical evaluation by research psychiatrists, different types of semi-structured interviews made by trained
research nurses and research psychiatrists, medical records, course of the disease and data frommultiple informants. Diagnosis was
made in accordance with the Diagnostic and Statistical Manual of Mental Disorders-Version IV (DSM-IV) or International Classifica-
tion of Diseases, 10th Revision (ICD-10) criteria. Controls were recruited from the Betula study, an ongoing longitudinal, prospective,
population-based study from the same geographic area (North Sweden) that is studying aging, health, and cognition in adults. Alle1 Cell 173, 1705–1715.e1–e12, June 14, 2018
subjects (cases and controls) participated after giving written informed consent and the regional Ethical Review Board at the Univer-
sity of Umeå approved all original studies and participation in the PGC. GWAS genotyping was performed at Broad Institute.
Andreassen, O j 19571808 j Norway (TOP) j scz_top8_eur
In the TOP study (Tematisk omrade psykoser), cases of European ancestry, born in Norway, were recruited from psychiatric hos-
pitals in the Oslo region. Patients were diagnosed according to SCID and further ascertainment details have been reported. Healthy
control subjects were randomly selected from statistical records of persons from the same catchment area as the patient groups. All
participants provided written informed consent and the human subjects protocol was approved by the Norwegian Scientific-Ethical
Committee and the Norwegian Data Protection Agency.
Blackwood, D j 19571811 j Edinburgh, UK j scz_edin_eur
Cases and controls were recruited from the southeast of Scotland, and ascertainment has been previously described as part of the
International Schizophrenia Consortium studies. All participating subjects gave written, informed consent and the human subjects
protocol was approved by the Scotland A Research Ethics Committee. DNA samples were genotyped at the Broad Institute.
Børglum, A j 19571808 j Denmark j scz_aarh_eur
DNA samples for all subjects were collected from blood spots systematically collected by the Danish Newborn Screening Bio-
bank), with case/control status established using the Danish Psychiatric Central Register. Cases were diagnosed clinically according
to ICD-10 criteria. Controls were selected to match the cases by birth cohort. The Danish Data Protection Agency and the ethics
committees in Denmark approved the human subjects protocol.
Bramon j 23871474 j Seven countries (PEIC, WTCCC2) j scz_pewb_eur
Bramon j 23871474 j Spain (PEIC, WTCCC2) j scz_pewb_eur
The Psychosis Endophenotypes International Consortium (PEIC) was part of WTCCC2. Samples were collected through seven
centers in Europe and Australia (the Institute of Psychiatry, King’s College London, London; GROUP (consisting of the University
of Amsterdam, Amsterdam; the University of Groningen, Groningen; Maastricht University Medical Centre, Maastricht; and the Uni-
versity of Utrecht, Utrecht); the University of Western Australia, Perth; the Universidad de Cantabria, Santander; the University of
Edinburgh, Edinburgh; Heidelberg University, Heidelberg and Ludwig-Maximilians-Universität München, Munich). To allow for a
DSM-IV diagnosis to be ascertained or ruled out, all participants (including controls and unaffected family members) underwent a
structured clinical interview with the Schedule for Affective Disorders and Schizophrenia (SADS), the Structured Clinical Interview
for DSM Disorders (SCID), or the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). We included cases with schizo-
phrenia and schizoaffective disorder. Participants in all groups were excluded if they had a history of neurological disease or
head injury resulting in loss of consciousness.
Buxbaum, J j 20489179 j New York, US & Israel j scz_msaf_eur
Samples contributed by Mount Sinai were derived from three cohorts. In all cohorts, ethical approval was obtained from all partici-
pating sites, and all subjects provided informed consent. Two of the cohorts were in a prior paper on copy number variation. One of
the cohorts was from the Mount Sinai brain bank, where DNA was extracted from postmortem samples, and another comprised of
patients ascertained in Israel. The third cohort included subjects more recently recruited through the Mount Sinai Conte Center.
Corvin, A j 19571811 j Ireland j scz_dubl_eur
The case sample was collected primarily in the Dublin area and the ascertainment procedure has been previously described. The
controls were recruited, from the same region through the Irish Blood Transfusion Services. All participants gave written, informed
consent and the collections were approved through the Federated Dublin Hospitals and Irish Blood Transfusion Services Research
Ethics Committees, respectively. DNA samples were genotyped at the Broad Institute.
Corvin, A; Riley, B j 22883433 j Ireland (WTCCC2) j scz_irwt_eur
The case sample was recruited from the Republic of Ireland and Northern Ireland. All cases had four Irish grandparents and ascer-
tainment details have been reported elsewhere. Ethics approval was obtained from all participating hospitals and centers. Controls
were blood donors from the Irish Blood Transfusion Service, whose Ethics Committee approved the human subjects protocol. All
participants gave written informed consent. Samples were genotyped at Affymetrix (Santa Clara, California, US) laboratory as
part of the WTCCC2 genotyping pipeline.
Ehrenreich, H j 20819981 j Germany (GRAS) j scz_gras
The Gottingen Research Association for Schizophrenia (GRAS) collection included cases recruited across 23 German hospitals.
Controls were unscreened blood donors recruited at the Georg-August-University according to national blood donation guidelines.
Cases completed a structured clinical interview and were diagnosed with DSM-IV schizophrenia or schizoaffective disorder. The
study was approved by the Georg-August-University ethics committee and local internal review boards of the participating centers.
All participants gave written informed consent.
Esko, T j 15133739 j Estonia (EGCUT) j scz_egcu_eur
The Estonian cohort comes from the population-based biobank of the Estonian Genome Project of University of Tartu (EGCUT).
The project was conducted according to the Estonian Gene Research Act and all participants provided informed consent (www.
biobank.ee). In total, 52,000 individuals aged 18 years or older participated in this cohort (33% men, 67% women). The population
distributions of the cohort reflect those of the Estonian population (83% Estonians, 14% Russians and 3% other). General practi-
tioners (GP) and physicians in the hospitals randomly recruited the participants. A Computer-Assisted Personal interview was con-
ducted over 1-2 ours at doctors’ offices. Data on demographics, genealogy, educational and occupational history, lifestyle andCell 173, 1705–1715.e1–e12, June 14, 2018 e2
anthropometric and physiological data were assessed. Schizophrenia was diagnosed prior to the recruitment by a psychiatrist ac-
cording to ICD-10 criteria and identified from the Estonian Biobank phenotype database. Controls were drawn from a larger pool of
genotyped biobank samples by matching on gender, age and genetic ancestry. All the controls were population-based and have not
been sampled for any specific disease.
Esko, T; Li, Q; Dominici E j 15133739, 24166486 j J&J and Roche cases, EGCUT controls j scz_jr3a_eur
Esko, T; Li, Q; Domenici E j 15133739, 24166486 j J&J and Roche cases, EGCUT controls j scz_jr3b_eur
Esko, T; Li, Q; Domenici E j 15133739, 24166486 j J&J and Roche cases, EGCUT controls j scz_jri6_eur
Esko, T; Li, Q; Dominici E j 15133739, 24166486 j J&J and Roche cases cases, EGCUT controls j scz_jrsa_eur
Cases were collected by Johnson and Johnson (J&J) and Roche as part of clinical collaborations with hospitals and outpatient
centers. Cases were diagnosed according to DSMIV criteria, with medical record review by a trained psychiatrist. There were reli-
ability trials across centers for the J&J studies. The J& J cases weremostly collected in Eastern Europe, with most coming from Esto-
nian and Russia (> 100); intermediate numbers from Austria, the Czech Republic, Latvia, Lithuania, and Spain (50-100); and smaller
collections from Bulgaria, Hungary, and Poland (< 50). The Roche cases were assessed with a structured psychiatric assessment by
trained interviewers. Most of the Eastern European controls were from the Estonian Biobank project (EGCUT) and were ancestrally
matched with cases from the J&J sample.
Gejman, P j 19571809 j US, Australia (MGS) j scz_mgs2_eur
European ancestry case samples were collected by the Molecular Genetics of Schizophrenia (MGS) collaboration across multiple
sites in the USA and Australia as described in detail elsewhere. Cases gave written informed consent, and IRBs at each collecting site
approved the human subjects protocol. A survey company (Knowledge Networks, under MGS guidance) collected the European
ancestry control sample and ascertainment is described in detail elsewhere. DNA samples were genotyped at the Broad Institute.
Gurling, H j 19571811 j London, UK j scz_uclo_eur
All cases and controls were collected by University College London and had both parents from England, Scotland or Wales. All
participants gave written informed consent and the UK National Health Service multicenter and local research ethics committee
approved the human subjects protocol. Further details on ascertainment are available elsewhere. The samples were genotyped
at the Broad Institute.
Jönsson, E j 19571808 j Sweden (Hubin) j scz_ersw_eur
Cases were recruited from northwestern Stockholm County and ascertainment has been described previously. Cases gave
informed consent and the human subjects protocol was approved by the ethical committees of the Karolinska Hospital and the
Stockholm Regional Ethical Committee. Controls were recruited either among subjects previously participating in biological research
at the Karolinska Institute or drawn from a representative register of the population of Stockholm County. All participants provided
informed consent.
Kirov, G j Not published j Bulgaria j scz_buls_eur
All cases were recruited from Bulgaria and had a history of hospitalization for treatment of schizophrenia. Controls were recruited
from the two largest cities in Bulgaria as previously described. All participants gave written informed consent and the study was
approved by local ethics committees at the participating centers.
Knight, J; Collier DA; Nisenbaum Lj Not published j Canada (Toronto) -US(Lilly)-US (MIGen)j scz_lktu_eur
Toronto cases were recruited by referral and advertisement. Diagnoses were made according to DSM-III or DSM-IV criteria
following interview and medical record review. US cases were recruited from schizophrenia clinical trials in a range of settings as
part of a trial with Eli Lilly. Diagnoses were made according to DSM-III or DSM-IV criteria following interview by psychiatrist andmed-
ical record review. No controls were sampled as part of the study, and ancestrally-matched controls were chosen from the Myocar-
dial Infarction Genetics Consortium (MIGen, dbGaP ID phs000294.v1.p1) that was genotyped with the same SNP array.
Lencz, T; Darvasi A j 23325106 j Israel j scz_ajsz_eur
Cases and controls were sampled from an Ashkenazi Jewish repository (Hebrew University Genetic Resource, http://hugr.
huji.ac.il). Patients were recruited from hospitalized inpatients at 7 medical centers in Israel and were diagnosed with DSM-IV
schizophrenia or schizoaffective disorder. Controls were sampled through the Israeli Blood Bank and did not report any chronic
disease or regularly prescribed medication at the time of assessment. Full ascertainment details have previously been reported.
Local ethics committees and the National Genetic Committee of the Israeli Ministry of Health approved the studies and all par-
ticipants gave informed, written consent.
Levinson, D j 22885689 j Six countries, WTCCC controls j scz_lacw_eur
Cases collected as part of a larger pedigree-based studywere partitioned into two subsamples. Caseswith two genotyped parents
were analyzed as trios (see PI Levinson, ms.scz_lemu_eur in the Trio section below). Unrelated cases who could not be used as part
of a trio were included as a separate case-control analysis, using independent controls, matched by ancestry and genotyping array,
from the Wellcome Trust Case Control Consortium. Cases were identified from different clinical settings (e.g., inpatients, outpatients
and community facilities) in six countries (Australia, France, Germany, Ireland, UK, and the US). Diagnoses were established using
semi-structured interviews, psychiatric records and informant reports. Case subjects were diagnosed with schizophrenia or schiz-
oaffective disorder according to DSM-III-R criteria. All protocols were approved by loci IRBs, and all cases provided written informed
consent.
Malhotra, A j 17522711 j New York, US j scz_zhh1_eure3 Cell 173, 1705–1715.e1–e12, June 14, 2018
The case and control subjects were recruited in the New York metropolitan area and ascertainment methods have been described
previously. All participants gave written, informed consent and the IRB of the North Shore-Long Island Jewish Health System
approved the human subjects protocols. DNA was genotyped at Zucker Hillside.
Mowry, B j 21034186 j Australia j scz_asrb_eur
These subjects were part of the Australian Schizophrenia Research Bank. The case sample was recruited in four Australian States
(New South Wales, Queensland, Western Australia and Victoria) through hospital inpatient units, community mental health services,
outpatient clinics and rehabilitation services, non-government mental illness support organizations, and, in the initial stages, through
a large-scale, national, multi-media advertising campaign. This sample is comprised of 509 cases from larger metropolitan centers of
Brisbane, Newcastle, Sydney, Melbourne, and Perth. Cases gave written informed consent, and the human subjects protocol was
initially approved by the Hunter New England Area Health Research Committee and subsequently approved by relevant Institutional
Ethics Committees in Brisbane, Sydney, Melbourne and Perth. Healthy controls were recruited throughmulti-media advertisements,
and other sources. Controls were from the metropolitan centers of Brisbane, Newcastle, Sydney, Melbourne, and Perth. Controls
gave written informed consent, and the human subjects protocol was approved by the Hunter New England Area Health Research
Committee and Institutional Ethics Committees in Brisbane, Sydney, Melbourne and Perth. The samples were genotyped in two
stages at the Hunter Medical Research Institute, University of Newcastle, Newcastle, Australia.
O’Donovan, M: Owen, M j 19571811 j Cardiff, UK j scz_caws_eur
The case sample included European ancestry schizophrenia cases recruited in the British Isles and described previously. All cases
gave written informed consent to. The study was approved by the Multicenter Research Ethics Committee in Wales and Local
Research Ethics Committees from all participating sites. The control sample used the Wellcome Trust CaseControl Consortium
(WTCCC) sample described elsewhere, but included similar numbers of individuals from the 1958 British Birth Cohort and a panel
of consenting blood donors (UK Blood Service). Samples were genotyped at Affymetrix service lab (San Francisco, USA).
O’Donovan, M: Owen, M: Walters, J j 22614287 j UK (CLOZUK) j scz_clm2_eur
O’Donovan, M: Owen, M: Walters, J j 22614287 j UK (CLOZUK) j scz_clo3_eur
CLOZUK caseswere taking the antipsychotic clozapine and had received a clinical diagnosis of treatment-resistant schizophrenia.
Patients taking clozapine provide blood samples to allow detection of adverse drug-effects. Through collaboration with Novartis (the
manufacturer of a proprietary form of clozapine, Clozaril), we acquired blood from people with treatment-resistant schizophrenia ac-
cording to the clozapine registration forms completed by treating psychiatrists as previously reported. The samples were genotyped
at the Broad Institute. The UKMulticenter Research Ethics Committee (MREC) approved the study. The controls were drawn from the
WTCCC2 control samples (3,000 from the 1958British Birth Cohort and3,000 samples from the UKBlood Service Control Group).
An additional 900 controls, held by Cardiff University, were recruited from the UK National Blood Transfusion Service. They were not
specifically screened for psychiatric illness. All control samples were from participants who provided informed consent.
Ophoff, R j 19571808 j Netherlands j scz_ucla_eur
The case sample consisted of inpatients and outpatients recruited through psychiatric hospitals and institutions throughout the
Netherlands. Cases with DSM-IV schizophrenia were included in the analysis. Further details on ascertainment are provided else-
where. Controls came from the University Medical Centre Utrecht and were volunteers with no psychiatric history. Ethical approval
was provided by local ethics committees and all participants gave written informed consent.
Palotie, A j 19571808 j Finland j scz_fi3m_eur
Palotie, A j Not published j Finnish j scz_fii6_eur
Finnish cases were drawn from a nationwide collection of families with schizophrenia spectrum disorders. The control sample was
derived from the Finnish Health 2000 survey. All participants provided written informed consent and approval was obtained from the
ethics committees at each location.
Pato, C j 19571811 j Portugal j scz_port_eur
Cases and controls lived in Portugal, the Azorean and Madeiran islands, or were the direct (firstor second-generation) Portugese
immigrant population in the US, as previously described. Controls were not biologically related to cases. All participants gave written
informed consent and the IRB of SUNYUpstateMedical University approved the protocol. The samples were genotyped at the Broad
Institute.
Petryshen, T j 24424392j Boston, US (CIDAR) j scz_cims_eur
Cases were recruited from inpatient and outpatient settings in the Boston area by clinician referral, through review of medical re-
cords, or through advertisements in local media. Cases were diagnosed with DSM-IV schizophrenia through a structured clinical
interview (SCID) by trained interviewers with review of medical records and a best estimate diagnostic procedure including reliability
trials across interviewers. A psychiatrist or a PhD-level mental health professional made the final diagnostic determination. Controls
were ascertained through local advertisements from the same geographical area. Ethical approval was provided by local ethics com-
mittees and all participants gave written informed consent.
Rietschel/Rujescu/Nöthen j 19571808 j Bonn/Mannheim, Germany j scz_boco_eur
These German samples were collected by separate groups within the MooDS Consortium in Mannheim, Bonn, Munich and Jena.
For the PGC analyses, the samples were combined by chip and ancestry. In Bonn/Mannheim, cases were ascertained as previously
described. Controls were drawn from three population-based epidemiological studies (PopGen), the Cooperative Health Research in
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the local ethics committees approved the human subjects protocols. Additional controls were randomly selected from a Munich-
based community sample and screened for the presence of anxiety and affective disorders using the Composite International Diag-
nostic Screener. Only individuals negative for the above mentioned disorders were included in the sample.
Rujescu, D j 19571808 j Munich, Germany j scz_munc_eur
For the Munich sample, cases were ascertained from the Munich area of Germany, as described previously. The controls were
unrelated volunteers randomly selected from the general population of Munich. All were screened to exclude a history of psycho-
sis/central neurological disease either personally or in a first-degree relative. All participants gave written informed consent and
the local ethics committees approved the human subjects protocols.
St Clair, D j 19571811 j Aberdeen, UK j scz_aber_eur
Ascertainment and inclusion/exclusion criteria for cases and controls have been previously described. All participating subjects
were born in the UK (95% Scotland) and gave written informed consent. Both local and multiregional academic ethical committee
approved the human subjects protocol. The samples were genotyped at the Broad Institute.
Sullivan, PF j 18347602 j US (CATIE) j scz_cati_eur
Cases were collected as part of the Clinical Antipsychotics Trials of Intervention Effectiveness (CATIE) project and ascertainment
was previously described. Participants were recruited frommultiple sites in the USAwith informed written consent and approval from
the IRBs at each CATIE site and the University of North Carolina (Chapel Hill). The control subjects were collected byMGS (described
above) and gave online informed consent andwere fully anonymized. There was no overlap with controls included in theMGS collab-
oration sample.
Sullivan, PF; Sklar P; Hultman C j 23974872 j Sweden j scz_swe1_eur
Sullivan, PF; Sklar P; Hultman C j 23974872 j Sweden j scz_s234_eur
Sullivan, PF; Sklar P; Hultman C j 23974872 j Sweden j scz_swe5_eur
Sullivan, PF; Sklar P; Hultman C j 23974872 j Sweden j scz_swe6_eur
Samples from the Swedish Schizophrenia Study were collected in a multi-year project and genotypes in six batches (sw1-6). All
procedures were approved by ethical committees at the Karolinska Institutet and the University of North Carolina, and all subjects
provided written informed consent (or legal guardian consent and subject assent). All samples were genotyped at the Broad Institute.
Cases with schizophrenia were identified via the Swedish Hospital Discharge Register which captures all public and private inpatient
hospitalizations. The register is complete from 1987 and is augmented by psychiatric data from 1973-1986. The register contains
International Classification of Disease discharge diagnoses made by attending physicians for each hospitalization. Case inclusion
criteria included R 2 hospitalizations with a discharge diagnosis of schizophrenia, both parents born in Scandinavia and age R
18 years. Case exclusion criteria included hospital register diagnosis of any medical or psychiatric disorder mitigating a confident
diagnosis of schizophrenia as determined by expert review. The validity of this case definition of schizophrenia was strongly sup-
ported by clinical, epidemiological, genetic epidemiological and genetic evidence. Controls were selected at random from Swedish
population registers, with the goal of obtaining an appropriate control group and avoiding ‘super-normal’ controls. Control inclusion
criteria included never being hospitalized for schizophrenia or bipolar disorder (given evidence of genetic overlapwith schizophrenia),
both parents born in Scandinavia and age of R 18 years.
Walters, J j 21850710 j Cardiff, UK (CogUK) j scz_cou3_eur
Cases were recruited from community mental health teams in Wales and England on the basis of a clinical diagnosis of schizo-
phrenia or schizoaffective disorder (depressed sub-type) as described previously. 35 Diagnosis was confirmed following a SCAN
interview and review of case notes followed by consensus diagnosis according to DSM-IV criteria. The samples were genotyped
at the Broad Institute. The UKMulticenter Research Ethics Committee (MREC) approved the study and all participants provided valid
informed consent.
Weinberger, D j 11381111 j NIMH CBDB j scz_lie2_eur
Weinberger, D j 11381111 j NIMH CBDB j scz_lie5_eur
Subjects were recruited from the Clinical Brain Disorders Branch of the NIMH ‘Sibling Study’ as previously described. In brief,
cases and controls gave informed consent and only participants of European ancestry were included in the current analysis. Cases
completed a structured clinical interview and were diagnosed with schizophrenia-spectrum disorders. Samples were genotyped at
the NIMH.
Wendland/Schubert j Pfizer j Not Published j Multiple countries j scz_pfla_eur
Pfizer contributed anonymized individual genotypes for cases from seven multi-center randomized, double-blind efficacy and
safety clinical trials (A1281063, A1281134, A1281148, A245-102, NRA7500001, NRA7500002, NRA7500003, and NRA7500004)
as well as a set of purchased samples (NRA9000099). Trial samples were collected for antipsychotic medications across outpatient
and inpatient treatment settings. All participating cases had a diagnosis of schizophrenia and were assessed using a structural clin-
ical interview by trained interviewers, with systematic procedures to quality-control diagnostic accuracy and reliability trials across
participating sites in the United States and internationally. Purchased blood samples were obtained from PrecisionMed International
by Pharmacia andUpjohnCorporation, andwere collected fromdiagnosed subjects with schizophrenia and schizoaffective disorder.
All studies were reviewed by both central and local institutional review boards, depending on the study site, before recruitment of
subjects started. Protocol amendments were approved while the study was in progress and before the data were unblinded. The
studies were conducted in conformity with the U.S. Food and Drug Administration Code of Federal Regulations (21CFR, Part 50)e5 Cell 173, 1705–1715.e1–e12, June 14, 2018
and the Declaration of Helsinki and its amendments, and were consistent with Good Clinical Practice and the applicable regulatory
requirements. Participants provided written informed consent before enrollment. An optional blood sample was collected from clin-
ical trial subjects for pharmacogenetic analysis to investigate potential associations between genetic variant drug response and gen-
eral characteristics of schizophrenia and related disorders. Sample collection was not required for participation in the original clinical
trials. The controls (A9011027) were recruited in a multi-site, cross-sectional, non-treatment prospective trial to collect data,
including DNA, from cognitive normal and free of psychiatric diseases elderly subjects in the US. Subjects were specifically recruited
to match the gender, age, and ethnicity information from the LEADe and UCSD MCI studies. The study described here is within the
scope of patient consent.
Werge, T j 19571808 j Denmark j scz_denm_eur
Cases were ascertained through psychiatric departments and twin pair studies, and were of Danish parentage for at least the prior
three generations. The controls were collected at the University of Aarhus, and included 500 medical students, all of Danish
parentage for at least three generations. All subjects gave written informed consent and the Danish Data Protection Agency and
the ethics committees of Denmark approved the human subjects protocol.
Bipolar Disorder
Adolfsson, R j Not published j Umeå, Sweden j bip_ume4_eur
Clinical characterization of the patients included the Mini-International Neuropsychiatric Interview (MINI), the Diagnostic Interview
for Genetic Studies (DIGS), the Family Interview for Genetic Studies (FIGS) and the Schedules for Clinical Assessment in Neuropsy-
chiatry (SCAN). The final diagnoses were made according to the DSM-IV-TR and determined by consensus of 2 research psychia-
trists. The unrelated Swedish control individuals, consisting of a large population-based sample representative of the general pop-
ulation of the region, were randomly selected from the ‘Betula study’.
Alda, M; Smoller, J j Not published j Nova Scotia, Canada; I2B2 controls j bip_hal2_eur
The case samples were recruited from patients longitudinally followed at specialty mood disorders clinics in Halifax and Ottawa
(Canada). Cases were interviewed in a blind fashion with the Schedule of Affective Disorders and Schizophrenia-Lifetime version
(SADS-L) and consensus diagnoses were made according to DSM-IV and Research Diagnostic Criteria (RDC). Protocols and pro-
cedures were approved by the local Ethics Committees and written informed consent was obtained from all patients before partic-
ipation in the study. Control subjects were drawn from the I2B2 (Informatics for Integrating Biology and the Bedside) project. The
study consists of de-identified healthy individuals recruited from a healthcare system in the Boston, MA, US area. The de-identifica-
tion process meant that the Massachusetts General Hospital Institutional Review Board elected to waive the requirement of seeking
informed consent as detailed by US Code of Federal Regulations, Title 45, Part 46, Section 116 (46.116).
Andreassen, OA j PMID:21926972 [PGC1], PMID:20451256 j Norway (TOP) j bip_top7_eur
In the TOP study (Tematisk omrade psykoser), cases of European ancestry, born in Norway, were recruited from psychiatric hos-
pitals in the Oslo region. Patients were diagnosed according to the SCID[REMOVED HYPERLINK FIELD] and further ascertainment
details have been reported. Healthy control subjects were randomly selected from statistical records of persons from the same
catchment area as the patient groups. The control subjects were screened by interview and with the Primary Care Evaluation of
Mental Disorders (PRIME-MD). None of the control subjects had a history of moderate/severe head injury, neurological disorder,
mental retardation or an age outside the age range of 18-60 years. Healthy subjects were excluded if they or any of their close
relatives had a lifetime history of a severe psychiatric disorder. All participants provided written informed consent and the human
subjects protocol was approved by the Norwegian Scientific-Ethical Committee and the Norwegian Data Protection Agency.
Andreassen, OA j Not published j Norway (TOP) j bip_top8_eur
The TOP8 bipolar disorder cases and controls were ascertained in the same way as the bip_top7_eur (TOP7) samples described
above, and recruited from hospitals across Norway.
Biernacka, JM; Frye, MA j 27769005 j Mayo Clinic, USA j bip_may1_eur
Bipolar cases were drawn from the Mayo Clinic Bipolar Biobank. Enrolment sites included Mayo Clinic, Rochester, Minnesota;
Lindner Center of HOPE/University of Cincinnati College of Medicine, Cincinnati, Ohio; and the University of Minnesota, Minneapolis,
Minnesota. Enrolment at each site was approved by the local Institutional Review Board approval, and all participants consented to
use of their data for future genetic studies. Participants were identified through routine clinical appointments, from in-patients
admitted in mood disorder units, and recruitment advertising. Participants were required to be between 18 and 80 years old and
be able to speak English, provide informed consent, and have DSM-IV-TR diagnostic confirmation of type 1 or 2 bipolar disorder
or schizoaffective bipolar disorder as determined using the SCID. Controls were selected from the Mayo Clinic Biobank. Potential
controls with ICD9 codes for bipolar disorder, schizophrenia or related diagnoses in their electronic medical record were excluded.
Blackwood, D j 18711365 [PGC1] j Edinburgh, UK j bip_edi1_eur
This sample comprised Caucasian individuals contacted through the inpatient and outpatient services of hospitals in South East
Scotland. A BD-I diagnosis was based on an interview with the patient using the SADS-L supplemented by case note review and
frequently by information from medical staff, relatives and caregivers. Final diagnoses, based on DSM-IV criteria were reached by
consensus between two trained psychiatrists. Ethnically-matched controls from the same region were recruited through the South
of Scotland Blood Transfusion Service. Controls were not directly screened to exclude those with a personal or family history of psy-
chiatric illness. The study was approved by the Multi-Centre Research Ethics Committee for Scotland and patients gave written
informed consent for the collection of DNA samples for use in genetic studies.Cell 173, 1705–1715.e1–e12, June 14, 2018 e6
Breen, G; Vincent, JB j 24387768; 19416921; 21926972 [PGC1] jLondon, UK; Toronto, Canada [BACC] j bip_bac1_eur
The total case/control cohort (N = 1922) includes 871 subjects from Toronto, Canada (N = 431 cases (160 male; 271 female); N =
440 controls (176 male; 264 female)), 1051 subjects from London, UK (N = 538 cases (180 male; 358 female); N = 513 controls (192
male; 321 female)). A summary of mean and median age at interview, age of onset (AOO), diagnostic subtypes (BD 1 versus BD 2),
presence of psychotic symptoms, suicide attempt and family history of psychiatric disorders has been provided previously for both
the Toronto and London cohorts. From the Toronto site (Centre for Addiction & Mental Health (CAMH)), BD individuals and unrelated
healthy controlsmatched for age, gender and ethnicity were recruited. Inclusion criteria for patients: a) diagnosedwith DSMIV/ICD 10
BD 1 or 2; b) 18 years old or over; c) Caucasian, of Northern and Western European origin, and three out of four grandparents also
N.W. European Caucasian. Exclusion criteria include: a) Use of intravenous drugs; b) Evidence of intellectual disability; c) Related to
an individual already in the study; d) Manias that only ever occurred in relation to or resulting from alcohol or substance abuse/depen-
dence, or medical illness; e) Manias resulting from non-psychotropic substance usage. The SCAN interview (Schedule for Clinical
Assessments in Neuropsychiatry) was used for subject assessment. Using the SCAN interview along with case note review, each
case was assigned DSM-IV and ICD 10 diagnoses by two independent diagnosticians, according to lifetime consensus best-esti-
mate diagnosis. Lifetime occurrence of psychiatric symptoms was also recorded using the OPCRIT checklist, modified for use
with mood disorders. Similar methods and criteria were also used to collect a sample of 538 BD cases and 513 controls for the Lon-
don cohort (King’s College London; KCL). Both studies were approved by respective institutional research ethics committees (the
CAMH Research Ethics Board (REB) in Toronto, and the College Research Ethics Committee (CREC) at KCL), and informed written
consent was obtained from all participants. GWAS results have previously been published for the entire KCL/CAMH cohort.
Corvin, A j 18711365 [PGC1] j Ireland j bip_dub1_eur
Samples were collected as part of a larger study of the genetics of psychotic disorders in the Republic of Ireland, under protocols
approved by the relevant IRBs and with written informed consent that permitted repository use. Cases were recruited from Hospitals
and Community psychiatric facilities in Ireland by a psychiatrist or psychiatric nurse trained to use the SCID. Diagnosis was based on
the structured interview supplemented by case note review and collateral history where available. All diagnoses were reviewed by an
independent reviewer. Controls were ascertained with informed consent from the Irish GeneBank and represented blood donors who
met the same ethnicity criteria as cases. Controls were not specifically screened for psychiatric illness.
Rietschel, M; Nöthen, MM, Cichon, S j 21926972 [PGC1] j BOMA-Germany I j bip_bonn_eur
Cases for the BOMA-Bipolar Study were ascertained from consecutive admissions to the inpatient units of the Department of Psy-
chiatry and Psychotherapy at the University of Bonn and at the Central Institute for Mental Health in Mannheim, University of Heidel-
berg, Germany. DSM-IV lifetime diagnoses of bipolar I disorder were assigned using a consensus best-estimate procedure, based on
all available information, including a structured interview with the SCID and SADS-L, medical records, and the family history method.
In addition, the OPCRIT checklist was used for the detailed polydiagnostic documentation of symptoms. Controls were ascertained
from three population-based studies in Germany (PopGen, KORA, and Heinz-Nixdorf-Recall Study). The control subjects were not
screened for mental illness. Study protocols were reviewed and approved in advance by Institutional Review Boards of the partici-
pating institutions. All subjects provided written informed consent.
Rietschel, M; Nöthen, MM; Schulze, TG; Reif, A; Forstner, AJ j 24618891 j BOMA-Germany II j bip_bmg2_eur
Cases were recruited from consecutive admissions to psychiatric in-patient units at the University Hospital Würzburg. All cases
received a lifetime diagnosis of BD according to the DSM-IV criteria using a consensus best-estimate procedure based on all avail-
able information, including semi-structured diagnostic interviews using the Association for Methodology and Documentation in Psy-
chiatry, medical records and the family history method. In addition, the OPCRIT system was used for the detailed polydiagnostic
documentation of symptoms.
Control subjects were ascertained from the population-based Heinz Nixdorf Recall (HNR) Study. The controls were not screened
for a history of mental illness. Study protocols were reviewed and approved in advance by Institutional Review Boards of the partici-
pating institutions. All subjects provided written informed consent.
Rietschel, M; Nöthen,MM; Schulze, TG; Bauer, M; Forstner, AJ;Müller-Myhsok, B j 24618891 jBOMA-Germany III j bip_bmg3_eur
Cases were recruited at the Central Institute of Mental Health in Mannheim, University of Heidelberg, and other collaborating psy-
chiatric hospitals in Germany. All cases received a lifetime diagnosis of BD according to the DSM-IV criteria using a consensus best-
estimate procedure based on all available information including structured diagnostic interviews using the AMDP, Composite Inter-
national Diagnostic Screener (CID-S), SADS-L and/or SCID, medical records, and the family history method. In addition, the OPCRIT
system was used for the detailed polydiagnostic documentation of symptoms. Controls were selected randomly from a Munich-
based community sample and recruited at the Max-Planck Institute of Psychiatry. They were screened for the presence of anxiety
and mood disorders using the CID-S. Only individuals without mood and anxiety disorders were collected as controls. Study proto-
cols were reviewed and approved in advance by Institutional Review Boards of the participating institutions. All subjects provided
written informed consent.
Hauser, J; Lissowska, J; Forstner, AJ j 24618891 j BOMA-Poland j bip_bmpo_eur
Cases were recruited at the Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland. All cases received
a lifetime diagnosis of BD according to the DSM-IV criteria on the basis of a consensus best-estimate procedure and structured diag-
nostic interviews using the SCID. Controls were drawn from a population-based case-control sample recruited by the Cancer-Center
and Institute of Oncology,Warsaw, Poland and a hospital-based case-control sample recruited by theNofer Institute of Occupationale7 Cell 173, 1705–1715.e1–e12, June 14, 2018
Medicine, Lodz, Poland. The Polish controls were produced by the International Agency for Research on Cancer (IARC) and the
Centre National de Génotypage (CNG) GWAS Initiative for a study of upper aerodigestive tract cancers. The controls were not
screened for a history of mental illness. Study protocols were reviewed and approved in advance by Institutional Review Boards
of the participating institutions. All subjects provided written informed consent.
Rietschel, M; Nöthen, MM; Rivas, F; Mayoral, F; Kogevinas, M; others j 24618891 j BOMA-Spain j bip_bmsp_eur
Cases were recruited at the mental health departments of the following five centers in Andalusia, Spain: University Hospital Reina
Sofia of Córdoba, Provincial Hospital of Jaen; Hospital of Jerez de la Frontera (Cádiz); Hospital of Puerto Real (Cádiz); Hospital Punta
Europa of Algeciras (Cádiz); and Hospital Universitario San Cecilio (Granada). Diagnostic assessment was performed using the
SADS-L; the OPCRIT; a review of medical records; and interviews with first and/or second degree family members using the Family
Informant Schedule and Criteria (FISC). Consensus best estimate BD diagnoses were assigned by two or more independent senior
psychiatrists and/or psychologists, and according to the RDC, and the DSM-IV. Controls were Spanish subjects drawn from a cohort
of individuals recruited in the framework of the European Community Respiratory Health Survey (ECRHS, http://www.ecrhs.org/).
The controls were not screened for a history of mental illness. Study protocols were reviewed and approved in advance by Institu-
tional Review Boards of the participating institutions. All subjects provided written informed consent.
Fullerton, J.M.; Mitchell, P.B.; Schofield, P.R.; Martin N.G.; Cichon, S. j 24618891 j BOMA-Australia j bip_bmau_eur
Cases were recruited at the Mood Disorder Unit, Prince of Wales Hospital in Sydney. All cases received a lifetime diagnosis of BD
according to the DSM-IV criteria on the basis of a consensus best-estimate procedure and structured diagnostic interviews using the
DIGS, FIGS, and the SCID. Controls were parents of unselected adolescent twins from the Brisbane Longitudinal Twin Study. The
controls were not screened for a history of mental illness. Study protocols were reviewed and approved in advance by Institutional
Review Boards of the participating institutions. All subjects provided written informed consent.
Grigoroiu-Serbanescu, M; Nöthen, MM j 21353194 j BOMA-Romania j bip_rom3_eur
Cases were recruited from consecutive admissions to the Obregia Clinical Psychiatric Hospital, Bucharest. Patients were admin-
istered the DIGS and FIGS interviews. Information was also obtained frommedical records and close relatives. The diagnosis of BP-I
was assigned according to DSM-IV criteria using the best estimate procedure. All patients had at least two hospitalized illness ep-
isodes. Population-based controls were evaluated using the DIGS to exclude a lifetime history of major affective disorders, schizo-
phrenia, schizoaffective disorders, and other psychoses, obsessive-compulsive disorder, eating disorders, and alcohol or drug
addiction.
Craddock, N, Jones, I, Jones, L j 17554300 j WTCCC j bip_wtcc_eur_sr-qc
Cases were all over the age of 17 year, living in the UK and of European descent. Recruitment was undertaken throughout the UK
and included individuals who had been in contact with mental health services and had a lifetime history of high mood. After providing
written informed consent, participants were interviewed by a trained psychologist or psychiatrist using a semi-structured lifetime
diagnostic psychiatric interview (Schedules for Clinical Assessment in Neuropsychiatry) and available psychiatric medical records
were reviewed. Using all available data, best-estimate life-time diagnoses were made according to the RDC. In the current study
we included cases with a lifetime diagnosis of RDC bipolar 1 disorder, bipolar 2 disorder or schizo-affective disorder, bipolar
type. Controls were recruited from two sources: the 1958 Birth Cohort study and the UK Blood Service (blood donors) and were
not screened for history of mental illness. All cases and controls were recruited under protocols approved by the appropriate
IRBs. All subjects gave written informed consent.
Kelsoe, J j 21926972 [PGC1] j USA (GAIN) j bip_gain_eur
Genetic Association Information Network (GAIN)/ The Bipolar Genome Study (BiGS) The BD sample was collected under the aus-
pices of the NIMH Genetics Initiative for BD, genotyped as part of GAIN and analyzed as part of a larger GWAS conducted by the
BiGS consortium. Approximately half of the GAIN sample was collected as multiplex families or sib pair families (waves 1-4), the
remainder were collected as individual cases (wave 5). Subjects were ascertained at 11 sites: Indiana University, John Hopkins
University, the NIMH Intramural Research Program, Washington University at St. Louis, University of Pennsylvania, University of
Chicago, Rush Medical School, University of Iowa, University of California, San Diego, University of California, San Francisco, and
University of Michigan. All investigations were carried out after the review of protocols by the IRB at each participating institution.
At all sites, potential cases were identified from screening admissions to local treatment facilities and through publicity programs
or advocacy groups. Potential cases were evaluated using the DIGS, FIGS, and information from relatives and medical records.
All information was reviewed through a best estimate diagnostic procedure by two independent and non-interviewing clinicians
and a consensus best-estimate diagnosis was reached. In the event of a disagreement, a third reviewwas done to break the tie. Con-
trols were from theNIMHGenetic Repository sample obtained byDr. P. Gejman through a contract to KnowledgeNetworks, Inc. Only
individuals with complete or near-complete psychiatric questionnaire data who did not fulfill diagnostic criteria for major depression
and denied a history of psychosis or BDwere included as controls for BiGS analyses. Controls werematched for gender and ethnicity
to the cases.
Kelsoe, J; Sklar, P; Smoller, J j [PGC1 Replication] j USA (FAT2; FaST, BiGS, TGEN) j bip_fat2_eur
Cases were collected from individuals at the 11 U.S. sites described for the GAIN sample. Eligible participants were age 18 or older
meeting DSM-IV criteria for BD-I or BD-II by consensus diagnosis based on interviews with the Affective Disorders Evaluation (ADE)
andMINI. All participants provided written informed consent and the study protocol was approved by IRBs at each site. Collection of
phenotypic data and DNA samples were supported by NIMH grants MH063445 (JW Smoller); MH067288 (PI: P Sklar), andMH63420Cell 173, 1705–1715.e1–e12, June 14, 2018 e8
(PI: V Nimgaonkar). The control samples were NIMH controls that were using the methods described in that section. The case and
control samples were independent of those included in the GAIN sample.
Kirov, G j 25055870 j Bulgarian trios j bip_butr_eur
All cases were recruited in Bulgaria from psychiatric inpatient and outpatient services. Each proband had a history of hospitalisa-
tion and was interviewed with an abbreviated version of the SCAN. Consensus best-estimate diagnoses were made according
to DSM-IV criteria by two researchers. All participants gave written informed consent and the study was approved by local ethics
committees at the participating centers.
Kirov, G j 25055870 j UK trios j bip_uktr_eur
The BD subjects were recruited from lithium clinics and interviewed in person by a senior psychiatrist, using abbreviated version of
the SCAN. Consensus best-estimate diagnoses weremade based on the interview and hospital notes. Ethics committee approval for
the study was obtained from the relevant research ethics committees and all individuals provided written informed consent for
participation.
Landén, M; Sullivan, PF; Sklar, P j [ICCBD] j Sweden (ICCBD) j bip_swa2_eur
The BD subjects were identified using the Swedish National Quality Register for Bipolar Disorders (BipoläR) and the Swedish Na-
tional Patient Register (using a validated algorithm requiring at least two hospitalizations with a BD diagnosis). A confirmatory tele-
phone interview with a diagnostic review was conducted. Additional subjects were recruited from the St. Göran Bipolar Project (Af-
fective Center at Northern Stockholm Psychiatry Clinic, Sweden), enrolling new and ongoing patients diagnosed with BD using
structured clinical interviews. Diagnoses were made according to the DSM-IV criteria (BipoläR and St. Göran Bipolar Project) and
ICD-10 (National Patient Register). The control subjects used were the same as for the SCZ analyses described above. All ascertain-
ment procedures were approved by the Regional Ethical Committees in Sweden.
Landén, M; Sullivan, PF; Sklar, P j [ICCBD] j Sweden (ICCBD) j bip_swei_eur
The cases and controls in the bip_swei_eur sample were recruited using the same ascertainment methods described for the bip_
swa2_eur sample.
Leboyer, M j [PGC1 replication] j France j bip_fran_eur
Cases with BD1 or BD2 and control samples were recruited as part of a large study of genetics of BD in France (Paris-Creteil,
Bordeaux, Nancy) with a protocol approved by relevant IRBs and with written informed consent. Cases were of French descent
for more than 3 generations were assessed by a trained psychiatrist or psychologist using structured interviews supplemented by
medical case notes, mood scales and self-rating questionnaire assessing dimensions.
Li, Q j 24166486; 27769005 j USA (Janssen), SAGE controls j bip_jst5_eur
The study included unrelated patientswith bipolar 1 disorder from6 clinical trials (IDs:NCT00253162,NCT00257075, NCT00076115,
NCT00299715, NCT00309699, and NCT00309686). Participant recruitment was conducted by Janssen Research & Development,
LLC (formerly known as Johnson& JohnsonPharmaceutical Research&Development, LLC) to assess the efficacy and safety of risper-
idone.Bipolar caseswerediagnosedaccording toDSM-IV-TRcriteria. Thediagnosisofbipolar disorderwasconfirmedby theSchedule
for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL) in NCT00076115, by
the SCID in NCT00257075 and NCT00253162, or by the MINI in NCT00299715 and NCT00309699, and NCT00309686, respectively.
Additional detailed descriptions of these clinical trials can be found at ClinicalTrials.gov. Only patients of European ancestry with
matching controls were included in the current analysis. Controls subjects were drawn from the Study of Addiction: Genetics and Envi-
ronment (SAGE, dbGaP Study Accession: phs000092.v1.p1). Control subjects did not have alcohol dependence or drug dependence
diagnoses; however, mood disorders were not an exclusion criterion.
McQuillin, A; Gurling, H j 18317468 [PGC1] j UCL (University College London), London, UK j bip_uclo_eur
The UCL sample comprised Caucasian individuals who were ascertained and received clinical diagnoses of bipolar 1 disorder ac-
cording to UK National Health Service (NHS) psychiatrists at interview using the categories of the International Classification of Dis-
ease version 10. In addition bipolar subjects were included only if both parents were of English, Irish, Welsh or Scottish descent and if
three out of four grandparents were of the same descent. All volunteers read an information sheet approved by theMetropolitanMed-
ical Research Ethics Committee who also approved the project for all NHS hospitals. Written informed consent was obtained from
each volunteer. The UCL control subjects were recruited from London branches of the National Blood Service, from local NHS family
doctor clinics and from university student volunteers. All control subjects were interviewed with the SADS-L to exclude all psychiatric
disorders.
Craddock, N; Jones, I; Jones, L j [ICCBD] j Cardiff and Worcester, UK (ICCBD-BDRN) j bip_icuk_eur
Cases were all over the age of 17 year, living in the UK and of European descent. Cases were recruited via systematic and not
systematic methods as part of the Bipolar Disorder Research Network project, provided written informed consent and were inter-
viewed using a semi-structured diagnostic interview, the Schedules for Clinical Assessment in Neuropsychiatry. Based on the infor-
mation gathered from the interview and case notes review, best-estimate lifetime diagnosis was made according to DSM-IV. Inter-
rater reliability was formally assessed using 20 randomly selected cases (mean k Statistic = 0.85). In the current study we included
caseswith a lifetime diagnosis of DSM-IV bipolar disorder or schizo-affective disorder, bipolar type. The BDRN study has UKNational
Health Service (NHS) Research Ethics Committee approval and local Research and Development approval in all participating NHS
Trusts/Health Boards.Controls were part of the Wellcome Trust Case Control Consortium common control set, which comprised
healthy blood donors recruited from the UK Blood Service and samples from the 1958 British Birth Cohort. Controls were note9 Cell 173, 1705–1715.e1–e12, June 14, 2018
screened for a history of mental illness. All cases and controls were recruited under protocols approved by the appropriate IRBs. All
subjects gave written informed consent.
Ophoff, RA j Not Published j Netherlands j bip_ucla_eur
The case sample consisted of inpatients and outpatients recruited through psychiatric hospitals and institutions throughout the
Netherlands. Cases with DSM-IV bipolar disorder, determined after interview with the SCID, were included in the analysis. Controls
were collected in parallel at different sites in the Netherlands and were volunteers with no psychiatric history after screening with the
(MINI). Ethical approval was provided by UCLA and local ethics committees and all participants gave written informed consent.
Paciga, S j [PGC1] j USA (Pfizer) j bip_pf1e_eur
This sample comprised Caucasian individuals recruited into one of three Geodon (ziprasidone) clinical trials (NCT00141271,
NCT00282464, NCT00483548). Subjects were diagnosed by a clinician with a primary diagnosis of Bipolar 1 Disorder, most recent
episode depressed, with or without rapid cycling, without psychotic features, as defined in the DSM-IV-TR (296.5x) and confirmed by
the MINI (version 5.0.0). Subjects also were assessed as having a HAM-D-17 total score of > 20 at the screening visit. The trials were
conducted in accordance with the protocols, International Conference on Harmonization of Good Clinical Practice Guidelines, and
applicable local regulatory requirements and laws. Patients gave written informed consent for the collection of blood samples for
DNA for use in genetic studies.
Pato, C j [ICCBD] j Los Angeles, USA (ICCBD-GPC)j bip_usc2_eur
Genomic Psychiatry Consortium (GPC) cases and controls were collected via the University of Southern California healthcare sys-
tem, as previously described. Using a combination of focused, direct interviews and data extraction frommedical records, diagnoses
were established using the OPCRIT and were based on DSM-IV-TR criteria. Age and gender-matched controls were ascertained
from the University of Southern California health system and assessed using a validated screening instrument and medical records.
Scott, L; Myer, RM; Boehnke, M j 19416921 [PGC1] j Michigan, USA (Pritzker and NIMH) j bip_mich_eur
The Pritzker Neuropsychiatric Disorders Research Consortium (NIMH/Pritzker) case and controls samples were from the NIMH
Genetics Initiative Genetics Initiative Repository. Cases were diagnosed according to DMS-III or DSM-IV criteria using diagnostic
interviews and/or medical record review. Cases with low confidence diagnoses were excluded. From each wave 1-5 available
non-Ashkenazi European-origin family, two BD1 siblings were included when possible and the proband was preferentially included
if available (n = 946 individuals in 473 sibling pairs); otherwise a single BD1 case was included (n = 184). The bipolar sibling pairs were
retained within the NIMH/Pritzker sample when individuals in more than one study were uniquely assigned to a study set. Controls
had non-Ashkenazi European-origin, were aged 20-70 years and reported no diagnosis with or treatment for BD or schizophrenia,
and that they had not heard voices that others could not hear. Individuals with suspected major depression were excluded based on
answers to questions related to depressive mood. NIMH controls were further selected as the best match(es) to NIMH cases based
on self-reported ancestry.
Sklar, P; Smoller, J j 18317468 [PGC1] j USA (STEP1) j bip_stp1_eur
The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) was a seven-site, national U.S., longitudinal
cohort study designed to examine the effectiveness of treatments and their impact on the course of BD that enrolled 4,361 partic-
ipants who met DSM-IV criteria for BD1, BD2, bipolar not otherwise specified (NOS), schizoaffective manic or bipolar type, or cyclo-
thymic disorder based on diagnostic interviews. From the parent study, 2,089 individuals whowere over 18 years of agewith BD1 and
BD2 diagnoses consented to the collection of blood samples for DNA. BD samples with a consensus diagnosis of BD1were selected
for inclusion in STEP1. Two groups of controls samples from the NIMH repository were used. One comprised DNA samples derived
from US Caucasian anonymous cord blood donors. The second were controls who completed the online self-administered psychi-
atric screen and were ascertained as described above, by Knowledge Networks Inc. For the second sample of controls only those
without history of schizophrenia, psychosis, BD or major depression with functional impairment were used.
Sklar, P; Smoller, J j 18711365 [PGC1] j USA (STEP2) j bip_stp2_eur
The STEP2 sample included BD-1 and BD-2 samples from the STEP-BD study described above along with BD-2 subjects from
UCL study also described above. The controls samples for this study were from the NIMH repository as described above for the
STEP1 study.
European ancestry, trio design
Schizophrenia
Kirov, G: Owen M j 22083728j Bulgaria j ms.scz_butr_eur
Families from Bulgaria were recruited if a proband had schizophrenia or schizoaffective disorder, both parents were available, and
all members of the trio agreed to participate in the study. Recruitment took place between 1999 and 2004 in several psychiatric hos-
pitals in Bulgaria. Ethical Committee approval was obtained from each of these hospitals. All probands and all parents received an
Information Sheet and signed Informed Consent Forms. All participants had attended mainstream schools, which at the time in
Bulgaria, excluded people with mental retardation. Probands were either in- or out-patients at the time of the study but each had
a history of hospitalization. A team of psychiatrists was trained in using the rating scales and methods of the study. We used the
SCAN instrument to perform an interview for psychotic and mood symptoms. This instrument has been translated into Bulgarian
and validated by one of its authors (A. Jablensky). Consensus diagnoses were made according to DSM-IV criteria on the basis of
an interview and inspection of hospital notes by two clinicians. If consensus was not attained, the patient was re-interviewed by a
research interview trained clinician and was excluded if consensus could still not be reached. In addition, approximately 23% ofCell 173, 1705–1715.e1–e12, June 14, 2018 e10
the sample was selected at random and re-interviewed by a research interview trained clinician. Hospital notes were also collected
for affected relatives in order to confirm diagnoses.
Levinson, D j 22885689 j Six countries j ms.scz_lemu_eur
Schizophrenia cases were included from the family sample of European-ancestry pedigrees described by Levinson et al. Partic-
ipants and their families in this trio study, probands were ascertained and recruited from different clinical settings (e.g., inpatients,
outpatients and community facilities) in six countries (Australia, France, Germany, Ireland, UK, and the US). (Unrelated individuals
were included as part of a case-control design, see Levinson, D, scz_lacw_eur above.) Diagnoseswere established using semi-struc-
tured interviews, psychiatric records and informant reports. Case probands were diagnosed with schizophrenia or schizoaffective
disorder according to DSM-III-R criteria. The trio-based analysis included families where there was at least one affected proband
and two available parents. Each affected sibling in such families was included, with the parents, as an independent trio. All protocols
were approved by loci IRBs, and all cases provided written informed consent.
Kirov, G: Owen, M j Not Published j Bulgaria j ms.scz_uktr_eur
All cases and parents were recruited from UK and had a history of hospitalization for treatment of schizophrenia. Diagnosis was
confirmed following a SCAN interview and review of case notes followed by consensus diagnosis according to DSM-IV criteria. The
samples were genotyped at the Broad Institute. All participants gave written informed consent and the study was approved by local
ethics committees at the participating centers. The samples were genotyped at the Broad Institute.
Genotype Quality Control
To ensure independence of the datasets, individuals were excluded until no individual showed a relatedness (pihat) value greater than
0.2 to any other individual in the collection, while preferentially keeping the case over the control for case-control related pairs. In total
1,795 BD cases, 1,165 SCZ cases and 27,274 controls were removed (most of which were previously known), leaving 20,129 BD
cases 33,426 SCZ cases and 54,065 controls for the final meta-analysis.
For analyses directly comparing BD and SCZ, we matched cases from both phenotypes on genotyping platform and ancestry,
resulting in 15,270 BD cases versus 23,585 SCZ cases. Hence, we were able to match 76% of BD cases and 71% of SCZ cases
for this case versus case analysis.
Among our entire dataset, 44%of the sample was female, 51%wasmale and 5%were unreported by the collection site. This work
focused explicitly on the autosomes and sought maximal power across the analyses, sex was not used except for during quality con-
trol and sex-specific analyses were not performed in this effort. Individual ages were not provided. For a subset of cases, we had
information for age of onset which were used in subphenotype specific analyses only.
Sub-phenotype Description
BD sub-phenotypes were collected by each study site using a combination of diagnostic instruments, case records and participant
interviews. Ascertainment details for each study site are described in the supplemental data of the PGCBipolarWorking Group paper
(Stahl et al., 2017). The selection of phenotypes for collection by this group was determined by literature searches in order to deter-
mine phenotypes with prior evidence for heritability. It was further refined dependent on the availability of phenotype data across a
range of study sites and the consistency by which the phenotypes were defined. Schizophrenia subphenotypes represent quantita-
tive traits extracted using factor analysis from a set of standard psychiatric assessments and represent four symptom dimensions
(manic, depressive, positive and negative). These subphenotypes were used previously (Ruderfer et al., 2014) but in this work we
have increased the sample size with additional cohorts being added.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quality Control, Imputation, Association Analysis and Polygenic Risk Score Testing
Quality control and imputation were performed on each of the study cohort datasets (n = 81), according to standards established by
the Psychiatric Genomics Consortium (PGC). The quality control parameters for retaining SNPs and subjects were: SNP missing-
ness < 0.05 (before sample removal); subject missingness (p < 0.02); autosomal heterozygosity deviation (j Fhet j < 0.2); SNP miss-
ingness < 0.02 (after sample removal); difference in SNPmissingness between cases and controls < 0.02; and SNP Hardy-Weinberg
equilibrium (p > 106 in controls or p > 1010 in cases). Genotype imputation was performed using the pre-phasing/imputation step-
wise approach implemented in IMPUTE2 (Howie et al., 2011) / SHAPEIT (Delaneau et al., 2013) (chunk size of 3 Mb and default pa-
rameters). The imputation reference set consisted of 2,186 phased haplotypes from the full 1000 Genomes Project dataset (August
2012, 30,069,288 variants, release ‘‘v3.macGT1’’), all variants align to human genome build 19 (hg19). After imputation, we used the
best guess genotypes (genotype probability > 0.8), for further robust relatedness testing and population structure analysis. Here we
required very high imputation quality (INFO > 0.8) and low missingness (< 1%) for further quality control. After linkage disequilibrium
(LD) pruning (r2 < 0.02) and frequency filtering (MAF > 0.05), there were 14,473 autosomal SNPs in the dataset. Principal component
estimation was done with the same collection of autosomal SNPs. We tested the first 20 principal components for phenotype
association (using logistic regression with study indicator variables included as covariates) and evaluated their impact on the
genome-wide test statistics using l. Thirteen principal components namely 1,2,3,4,5,6,7,8,10,12,15,18,20 were included in all asso-
ciation analyses (l = 1.45). Analytical steps were repeated for SCZ versus BD analysis.e11 Cell 173, 1705–1715.e1–e12, June 14, 2018
We performed four main association analyses (Figure 1), i.e., (i) GWAS of BD and SCZ as a single combined case phenotype, as
well as disorder-specific GWAS using independent control sets in (ii) BD cases versus BD controls and (iii) SCZ cases versus SCZ
controls, and (iv) association analysis of SCZ cases versus BD cases. For all GWS loci from the GWAS of BD and SCZ versus controls
we identified any GWS loci within 1Mb from the extent of the locus in the previously published PGC SCZ versus controls (Schizo-
phreniaWorking Group of the Psychiatric Genomics Consortium, 2014) and themost recent PGCGWAS of BD versus controls (Stahl
et al., 2017) and performed conditional analysis. Specifically, we transformed the genotype probabilities of the disease variant into
dosages and used it as an additional covariate for the association analysis for the BD+SCZ versus controls index SNP. This was done
within each cohort and anOR based inverse SEweightedmeta-analysis was performed for the final result. All datasets were included
except for those with trios.
Summary-data-based Mendelian Randomization
Summary-bata-dasedMendelian randomizatiaon (SMR) (Zhu et al., 2016) is a method that integrates summary level GWAS data with
gene expression quantitative trait loci (eQTL) identified in independent datasets. This integration aims to identify variants that have
pleotropic effects on expression of a given gene and the phenotype. While significant findings may indeed reflect a causal path from
variant to phenotype through expression, it is impossible to discern statistically between pleiotropy and causality. However, the
method can remove linkage as driving the result, and uses the data available to prioritise among genes in genomic regions that
show association with disease. We used SMR as a statistical fine-mapping tool applied to the SCZ versus BD GWAS results to iden-
tify loci with strong evidence of causality via gene expression. SMR analysis is limited to significant (FDR < 0.05) cis SNP-expression
quantitative trait loci (eQTLs) with MAF > 0.01. eQTLs passing these thresholds were combined with GWAS results in the SMR test,
with significance (pSMR) reported at a Bonferroni-corrected threshold for each eQTL dataset. The eQTL architecture may differ be-
tween genes. For example, through LD, many SNPs can generate significant associations with the same gene, but in some instances
multiple SNPsmay be independently associatedwith the expression of a gene. After identification of significant SNP-expression-trait
association through the SMR test, a follow-up heterogeneity test aims to prioritize variants by excluding regions for which there is
conservative evidence for multiple causal loci (pHET < 0.05). SMR analyses were conducted using eQTL data from whole peripheral
blood (Westra et al., 2013), dorsolateral prefrontal cortex generated by the CommonMind Consortium8, and 11 brain sub-regions
from the GTEx consortium (The GTEx Consortium, 2015).
Regional joint GWAS
Summary statistic Z-scores were calculated for each marker in each of the four main GWAS results, using the logistic regression co-
efficient and its standard error. Rare SNPs (MAF < 0.01), and SNPs with a low INFO score (< 0.3) in either dataset were removed. The
causal variant relationships between SCZ and BD were investigated using the Bayesian method software pw-gwas (v0.2.1), with
quasi-independent regions determined by estimate LD blocks in an analysis of European individuals (n = 1,703)(Berisa and Pickrell,
2016; Pickrell et al., 2016). Briefly, pw-gwas takes a Bayesian approach to determine the probability of five independent models of
association. (1) There is no causal variant in BD or SCZ; (2) a causal variant in BD, but not SCZ (3); a causal variant in SCZ, but not BD;
(4) a shared causal variant influencing both BD and SCZ; (5) two causal variants where one influences BD, and one influences SCZ
(Figure 2). The posterior probability of each model is calculated using model priors, estimated empirically within pw-gwas. Regions
were considered to support a particular model when the posterior probability of the model was greater than 0.5.
Regional SNP-heritability estimation
We calculated local SNP-heritability independently for SCZ and BD using the Heritability Estimator from Summary Statistics (HESS)
software (Shi et al., 2016) for each of the independent regions defined above. The sum of these regional estimates is the total SNP-
heritability of the trait. To calculate local SNP-heritability HESS requires reference LD matrices representative of the population from
which the GWAS samples were drawn. We utilized the 1000 genomes European individuals as the reference panel (The 1000 Ge-
nomes Project Consortium, 2015). Unlike pw-gwas (Pickrell et al., 2016), HESS does not assume that only one causal variant can
be present in each region.
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Figure S1. Regional Association Plot and Forest Plot for the First Genome-wide Significant Hit in the SCZ versus BD GWAS, Related to
Figure 1B
(A) Association results for region chromosome 1 from 173.3 kb to 175.1 kb; most significant variant is marked with a diamond, and other variants are colored
based on their linkage disequilibrium with that variant.
(B) Forest plot including effect size and 95% confidence interval for each of the 14 cohorts and the meta-analysis.
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Figure S2. Regional Association Plot and Forest Plot for the Second Genome-wide Significant Hit in the SCZ versus BD GWAS, Related to
Figure 1B
(A) Association results for region chromosome 20 from 47.4 kb to 48.1 kb; most significant variant is marked with a diamond, and other variants are colored based
on their linkage disequilibrium with that variant.
(B) Forest plot including effect size and 95% confidence interval for each of the 14 cohorts and the meta-analysis.
Figure S3. Detailed Association of DCAKD from SMR, Related to Method Details, Summary-Data-Based Mendelian Randomization
Results at the DCAKD locus from SMR analysis of SCZ versus BD. Top plot, brown dots represent the P values for SNPs from SCZ versus BD GWAS, diamonds
represent theP values for probes from the SMR test. Bottom plot, the eQTLP values of SNPs from theWestra study for the ILMN_1811648 probe taggingDCAKD.
The top and bottom plots include all the SNPs available in the region in the GWAS and eQTL summary data, respectively, rather than only the SNPs common to
both datasets. Highlighted in red is the gene (DCAKD) that passed the SMR and HEIDI tests.
Figure S4. Heritability Estimates for BD and SCZ in Genome-wide Significant Regions of BD and SCZ, Related to Method Details, Regional
SNP-Heritability Estimation
Regional SNP-heritability estimates for SCZ andBD stratified bywhether the region contains themost significant variant in a genome-wide significant locus in BD,
SCZ, neither or both.
